US Pat. No. 9,081,148

SYSTEMS, METHODS AND COMPUTER-ACCESSIBLE MEDIUM WHICH PROVIDE MICROSCOPIC IMAGES OF AT LEAST ONE ANATOMICAL STRUCTURE AT A PARTICULAR RESOLUTION

The General Hospital Corp...

1. An apparatus for providing at least one electro-magnetic radiation to at least one sample, comprising:
a plurality of wave-guiding arrangements configured to (i) provide the at least one electro-magnetic radiation along different
paths, and (ii) at a point of emission of each of the wave guiding arrangements, cause a phase of each of the at least one
electro-magnetic radiation to have a predetermined value; and

at least one lens arrangement which is configured to receive the at least one electro-magnetic radiation from the wave-guiding
arrangements, and generate a focus-spot radiation to have a diameter that is smaller than a diffraction limited spot on or
in the sample.

US Pat. No. 9,408,539

SYSTEMS, METHODS AND COMPUTER-ACCESSIBLE MEDIUM WHICH PROVIDE MICROSCOPIC IMAGES OF AT LEAST ONE ANATOMICAL STRUCTURE AT A PARTICULAR RESOLUTION

The General Hospital Corp...

1. An apparatus for providing at least one electro-magnetic radiation to at least one sample, comprising:
a pre-fabricated optical mask;
a plurality of wave-guiding arrangements configured to (i) provide the at least one electro-magnetic radiation along different
paths, and (ii) at a point of emission of each of the wave guiding arrangements, forward each of the at least one electro-magnetic
radiation to the optical mask, which causes a phase of each of the at least one electro-magnetic radiations to have a predetermined
value; and

at least one lens arrangement which is configured to receive the at least one electro-magnetic radiation from the wave-guiding
arrangements, and generate a focus-spot radiation which has an extended focal depth.

US Pat. No. 9,198,568

METHODS AND SYSTEMS OF MATCHING VOICE DEFICITS WITH A TUNABLE MUCOSAL IMPLANT TO RESTORE AND ENHANCE INDIVIDUALIZED HUMAN SOUND AND VOICE PRODUCTION

The General Hospital Corp...

1. A method of providing a customized vocal treatment to a subject having a vocal dysfunction caused by a diminished pliability
or absence of phonatory mucosa, the method comprising
assessing both a cause of the subject's vocal dysfunction and the subject's vocal needs;
selecting a specific vocal implant to provide a mucosal tissue with sufficient pliability to produce an approximate desired
level of dynamic variation of vocal parameters of pitch or phonation threshold pressure, or both and vocal control in the
subject based on both the cause of the subject's vocal dysfunction and the subject's vocal needs, wherein the vocal implant
is a liquid, a gel, or a solution of one or more polymers; and

implanting the selected vocal implant in a location within glottal, supraglottal, subglottal, or pharyngeal mucosal tissue
in the subject that achieves the desired level of dynamic variation of vocal parameters and vocal control to provide a customized
vocal treatment specific to the subject's vocal dysfunction and needs.

US Pat. No. 9,265,764

USES OF CHEMICALS TO MODULATE GSK-3 SIGNALING FOR TREATMENT OF BIPOLAR DISORDER AND OTHER BRAIN DISORDERS

Massachusetts Institute o...

9. A method for treating bipolar disorder in a subject, comprising administering a GSK-3 inhibitor having an IC50 of less than 1 mM to a subject in an effective amount to treat the bipolar disorder based on said subject being indicated
or diagnosed to have bipolar disorder, wherein the subject is non-responsive to lithium.

US Pat. No. 9,447,030

INHIBITORS OF HISTONE DEACETYLASE

Massachusetts Institute o...

1. A compound of formula I:
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein:
J? is selected from NH2, OH, and SH;

each X is independently selected from hydrogen, deuterium, methyl, CF3, and halogen;

R5 is selected from C2-C8 alkenyl; (CH2)u-5-6 membered, saturated, unsaturated, or partially unsaturated heterocyclic ring: (CH2)v—C4-C8 cycloalkyl ring; (C1-C8-alkyl)w-C4-C8cycloalkenyl ring; (CH2)s-aromatic ring; and (CH2)s-heteroaromatic ring; wherein said heterocyclic ring, cycloalkyl ring, cycloalkenyl ring, heteroaromatic ring, and aromatic
ring are unsubstituted or substituted with one or more Ry, and said alkenyl is substituted with one or more RT;

R2aR2bR2cV(CH2)tU— is


b is selected from 0, 1, 2, and 3;
a is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
each Rx is independently selected from (CH2)zNH2, (CH2)zNHR3, (CH2)zNR3R3, OR3, OCF3, OCH2F, OCHF2, (CH2)z-aromatic ring, (CH2)z-heterocyclic ring, hydroxyl, halogen, C1-C8 alkyl, (C1-C8 alkyl)CF3, (C1-C8 alkyl)OH, C(O)R3, (CH2)zC(O)NH2, (CH2)zC(O)NHR3, (CH2)zC(O)NR3R3, (CH2)zNHC(O)R4, and (CH2)zNR4C(O)R4;

or taken together two Rx attached to the same carbon atom form ?O;

or taken together two Rx form a C3-C8 cycloalkyl ring, C4-C8 cycloalkenyl ring, or 3 to 8 membered, saturated or partially unsaturated heterocyclic ring, wherein said cycloalkyl ring,
cycloalkenyl ring, and heterocyclic ring are unsubstituted or substituted with one or more Rz;

or taken together two Rx form an aromatic ring or heteroaromatic ring, wherein said aromatic ring and heteroaromatic ring are unsubstituted or substituted
with one or more Rz;

each Rz is independently selected from halogen, C1-C4 alkyl, OH, OR3, CF3, OCF3, OCH2F, OCHF2, NH2, NHR3, NR3R3, and C(O)CH3;

each R3 is independently selected from C1-C8 alkyl and O(C1-C8 alkyl);

each R4 is independently selected from C1-C8 alkyl and CF3;

each Ry is independently selected from halogen, OR6, NH2, NHR6, NR6R6, OH, CF3, aromatic ring, C(O)R6, C1-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkynyl, wherein each R6 is independently C1-C8 alkyl;

each RT is independently selected from hydrogen, halogen, Si(R3)3, phenyl, and C1-C8 alkyl;

u is selected from 0, 1, and 2;
v? is selected from 0, 1, and 2;

w is selected from 0, 1, and 2;
s is selected from 0, 1, and 2; and
each z is independently selected from 0, 1, 2, and 3.

US Pat. No. 9,244,071

COMPOSITIONS AND METHODS FOR ASSESSING CYTOTOXICITY OF SINGLE CELLS

Massachusetts Institute o...

1. A method of assessing cytotoxicity of single cells using arrays of microwells, the method comprising steps of:
monitoring lysis of target cells in microwells that contain a single effector cell and at least one target cell; and
simultaneously profiling activation markers or secreted soluble mediators,
wherein the monitoring comprises a step of detecting lysis of said target cells by said single effector cell using a fluorescent
indicator; and

wherein the profiling comprises a step of contacting the microwells with a substrate, wherein a surface of the substrate contains
thereon agents that bind to said activation markers or secreted soluble mediators.

US Pat. No. 9,173,910

COMPOSITIONS OF MICROBIOTA AND METHODS RELATED THERETO

The General Hospital Corp...

1. A method of altering relative abundance of microbiota in a subject comprising administering to the subject an effective
dose of a composition consisting essentially of substantially purified Verrucomicrobia; wherein the subject has a disorder
selected from the group consisting of: obesity, metabolic syndrome, insulin deficiency, insulin-resistance related disorders,
glucose intolerance, diabetes, non-alcoholic fatty liver, and abnormal lipid metabolism.
US Pat. No. 9,301,926

LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER

Massachusetts Institute o...

1. A method of treating a tumor of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, comprising:
deploying a drug-eluting device into a tissue site of a patient in need of treatment, the device comprising:
a film which comprises a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from
about 2 ?m to about 1000 ?m; and

a flexible biocompatible substratum to which the film is adhered, the substratum comprising a patch or mesh; and
releasing a therapeutically effective amount of the chemotherapeutic drug from the film to the tissue site to treat the tumor,
wherein the release of the therapeutically effective amount of the chemotherapeutic drug from the film is controlled by in
vivo degradation of the polymer at the tissue site,

wherein deploying the device comprises implanting the device directly onto the tumor.
US Pat. No. 9,216,188

HYDROGELS FOR VOCAL CORD AND SOFT TISSUE AUGMENTATION AND REPAIR

The General Hospital Corp...

1. A method of treating a subject having phonatory mucosa with decreased pliability causing diminished functional vibratory
capacity and diminished phonation, the method comprising
locating a phonatory mucosa with diminished functional vibratory capacity in the subject; and
injecting into the phonatory mucosa a hydrogel material that comprises an elastic shear modulus ranging from about 15 to about
121 Pa measured at a frequency of 10 Hz in an amount effective to increase pliability of the phonatory mucosa sufficiently
to allow the phonatory mucosa to vibrate and improve phonation;

wherein the hydrogel material comprises a first cross-linked synthetic polymer and a second polymer,
wherein the first cross-linked synthetic polymer comprises a cross-linked form of polyethylene glycol, polylysine, polyvinyl
alcohol, or hyaluronic acid, and

wherein the second polymer is selected from the group consisting of polyethers, polyacrylates, polyesters, polyanhydrides,
polyols, polypeptides, polyvinyl alcohols, proteins, polysaccharides, gelatins, elastins, collagens, celluloses, methylcelluloses,
hyaluronic acid, dextrans, alginates, and derivatives thereof, and

wherein the hydrogel material comprises an interpenetrating or semi-interpenetrating network of the first and second polymers.

US Pat. No. 9,415,550

SYSTEM, METHOD, AND COMPUTER-ACCESSIBLE MEDIUM FOR FABRICATION MINIATURE ENDOSCOPE USING SOFT LITHOGRAPHY

The General Hospital Corp...

1. A method for providing a diffractive configuration in an optical arrangement, comprising:
providing an elastomeric material with at least one patterned surface;
connecting the elastomeric material with at least one portion of a waveguide arrangement using a pre-polymer adhesive composition;
and

causing the pre-polymer adhesive composition to polymerize so as to form the diffractive configuration which at least approximately
replicates a structure or at least one feature of the elastomeric material.

US Pat. No. 9,044,606

METHODS AND DEVICES FOR ACTIVATING BROWN ADIPOSE TISSUE USING ELECTRICAL ENERGY

Ethicon Endo-Surgery, Inc...

1. A medical method, comprising:
positioning a device in contact with tissue of a patient proximate to a depot of brown adipose tissue; and
activating the device to deliver an electrical signal to the patient to activate the brown adipose tissue and increase energy
expenditure of the brown adipose tissue, the electrical signal having a modulating signal and a carrier signal, wherein the
electrical signal is continuously delivered to the patient for a predetermined amount of time in a range of one day to four
weeks.

US Pat. No. 9,381,219

BROWN ADIPOCYTE MODIFICATION

Ethicon Endo-Surgery, Inc...

1. A composition for modifying brown adipose tissue to treat obesity comprising: a vector expressing uncoupling protein-1
(UCP-1) and a gene for a receptor selected from the group consisting of: thyroid hormone receptor (TR), peroxisome proliferators-activated
receptor (PPAR), ?-adrenergic receptor, transforming growth factor receptor, free fatty acid receptor and low density lipoprotein
receptor; and a pharmaceutically acceptable carrier.

US Pat. No. 9,320,751

MODIFIED SAPONINS FOR THE TREATMENT OF FUNGAL INFECTIONS

The General Hospital Corp...

1. A method of treating a fungal infection in a subject, the method comprising administering to the subject a therapeutically
effective amount of a compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or OC(O)RA;

R2 is H or OH;

R3 is H, C(O)ORA, CH2ORA, CH2OC(O)RA;

R4 and R5 are each independently H or OC(O)RB;

RA is H or C1-6 alkyl;

RB is C2-6 alkenyl; and

Gly is

US Pat. No. 9,096,594

KINASE INHIBITORS AND METHODS OF USE THEREOF

The Broad Institute, Inc....

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof,
wherein
R1 and R2 are independently selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl, and
optionally substituted heteroaryl; or R1 and R2 are taken together with their intervening atoms to form an optionally substituted 3- to 7-membered saturated carbocyclic or
heterocyclic ring, wherein the ring formed by R1 and R2 may be optionally fused to an aryl or heteroaryl ring;

R3 is selected from the group consisting of hydrogen, halo, —CN, —NO2, optionally substituted aliphatic, optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted
heteroaryl, —ORA, —N(RB)2, —SRA, —C(?O)RA, —C(?O)ORA, —C(?O)SRA, —C(?O)N(RB)2, —OC(?O)RA, —NRBC(?O)RA, —NRBC(?O)N(RB)2, —OC(?O)N(RB)2, —NRBC(?O)ORA, —SC(?O)RA, —C(?NRB)RA, —C(?NRB)N(RB)2, —NRBC(?NRB)RB, —C(?S)RA, —C(?S)N(RB)2, —NRBC(?S)RA, —S(?O)RA, —SO2RA, —NRBSO2RA, and —SO2N(RB)2;

each RA is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

each RB is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two
RB groups are taken together with their intervening atoms to form an optionally substituted heterocyclic ring;

R4a and R4b are hydrogen;

R5a and R5b are independently selected from the group consisting of hydrogen, halo, —CN, —ORA, —N(RB)2, and optionally substituted aliphatic, or R5a and R5b are taken together with their intervening atoms to form an optionally substituted 3- to 7-membered saturated carbocyclic or
heterocyclic ring; and

R6a and R6b are hydrogen.

US Pat. No. 9,624,307

FACTOR XII INHIBITORS FOR THE TREATMENT OF SILENT BRAIN ISCHEMIA AND ISCHEMIA OF OTHER ORGANS

The General Hospital Corp...

1. A method of treating small ischemic injuries in a patient, comprising administering to the patient an effective amount
of an inhibitor of Factor XII (FXII) to treat the small ischemic injuries, wherein the administering is performed before,
during, and/or after a medical procedure in the patient comprising contact with at least one of:
(a) the patient's heart,
(b) at least one blood vessel in the patient chosen from: the aorta, the aortic arch, a carotid artery, a coronary artery,
brachiocephalic artery, vertebrobasilar circulation, intracranial arteries, renal artery, a hepatic artery, a mesenteric artery,
and/or a blood vessel of the arterial system cranial to the heart, and

(c) a venous blood vessel in the patient if the patient has a known septal defect;
wherein the medical procedure of (a), (b), and (c) comprises release of at least one microembolus in at least one of said
heart and blood vessels of (a), (b), and (c) in the body.

US Pat. No. 9,623,023

CLASS OF NON-STIMULANT TREATMENT AND ADHD AND RELATED DISORDERS

The Florida State Univers...

1. A method comprising:
administering an effective amount of nor-binaltorphimine (nor-BNI) or a nor-BNI analog in the absence of a stimulant to an
individual having Attention Deficit/Hyperactivity Disorder (ADHD), thereby reducing the symptoms of the disorder in the individual.

US Pat. No. 9,115,402

COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS

Dana-Farber Cancer Instit...

1. A method of identifying subject-specific peptides and preparing a subject-specific immunogenic composition comprising said
subject-specific peptides that upon administration presents said subject-specific peptides to the subject's immune system,
wherein the subject has a tumor and said subject-specific peptides are specific to the subject and the subject's tumor, said
method comprising:
sequencing nucleic acid sample of the subject's tumor and of a non-tumor sample of the subject,
identifying 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 sequences comprising tumor-specific non-silent
mutations not present in the non-tumor sample;

producing 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 subject-specific peptides encoded by said 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 sequences comprising tumor-specific non-silent mutations non present
in the non-tumor sample

measuring binding of said produced subject-specific peptides to a HLA protein of said subject,
wherein each of said subject-specific peptides has a different tumor neo-epitope that is an epitope specific to the tumor
of the subject, from the neo-epitopes identified in tumor specific mutations,

wherein each neo-epitope is an expression product of a tumor-specific non-silent mutation not present in the non-tumor sample
and each neo-epitope binds to a HLA protein of the subject,

wherein said subject-specific peptides have a point mutation and bind to HLA proteins of the subject with an IC50 less than
500 nM;

formulating said subject-specific immunogenic composition for administration to the subject so that upon administration said
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 subject-specific peptides are presented to the subject's immune
system,

wherein said immunogenic composition comprises:
said 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 subject-specific peptides, comprising:
(1) a peptide that has a non-synonymous mutation leading to different amino acids in comparison with a protein of the non-tumor
sample; or

(2) a peptide having a read-through mutation in which a stop codon is modified or deleted, leading to translation of a longer
protein in comparison with a protein of the non-tumor sample with a novel tumor-specific sequence at the C-terminus; or

(3) a peptide that has a splice site mutation that leads to the inclusion of an intron in the mature mRNA and thus has a unique
tumor-specific protein sequence; or

(4) a peptide representing a chromosomal rearrangement that has Given rise to a chimeric protein with tumor-specific sequences
at the junction of two proteins of the non-tumor sample and thus represents a gene fusion;

or (5) a peptide representing in comparison with a protein of the non-tumor sample a frameshift mutation or deletion that
leads to a new open reading frame and a novel tumor-specific protein sequence.

US Pat. No. 9,164,094

BIOMARKERS TO IDENTIFY HIV-SPECIFIC T-CELL SUBSETS

Dana-Farber Cancer Instit...

1. A method of classifying an immune response in an individual infected with HIV comprising:
obtaining a biological sample from an individual infected with HIV;
determining an expression profile of HIV specific T-cells from said HIV-infected individual by determining hybridization of
a nucleic acid in said sample to a probe on a microarray, wherein said expression profile comprises an expression level of
at least two genes selected from those presented in FIG. 11;

comparing said expression profile to at least one of:
a. the expression profile of T-cells from a subject that is not infected with HIV;
b. the expression profile of HIV-specific T-cells that are controllers; and
c. the expression profile of HIV-specific T-cells that are chronic progressors; and
determining if said individual is a controller or a chronic progressor, thereby classifying-an immune response.

US Pat. No. 9,422,517

MICROSCALE AND NANOSCALE STRUCTURES FOR MANIPULATING PARTICLES

The General Hospital Corp...

1. A method of manipulating particles in a fluid sample, the method comprising:
introducing a fluid sample comprising first particles having a first diameter, second particles having a second diameter that
is less than the first diameter, and third particles having a third diameter that is less than the second diameter into a
fluidic device comprising:

a fluid path; and
an array of obstacles disposed in the fluid path, each obstacle comprising a plurality of aligned nanostructures comprising
nanotubes or nanorods or both nanotubes and nanorods, wherein gaps between the obstacles in the array permit particles having
diameters less than the first diameter to flow through the gaps between obstacles, and wherein spaces between the nanostructures
render each obstacle porous such that the porosity of the obstacles permits particles having diameters less than the second
diameter to flow through the obstacle;

flowing the fluid sample through the device;
capturing the first particles with the array of obstacles;
capturing at least some of the second particles within the array of obstacles at obstacle outer boundaries defined by a plurality
of obstacles in the array; and

capturing at least some of the third particles within one or more obstacles in the array.
US Pat. No. 9,114,148

MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS

University of Cincinnati,...

1. A method of increasing cardiac contractility and reducing morphological deterioration associated with cardiac remodeling
in a subject with existing heart failure, said method comprising:
directly introducing in vivo an effective amount of a viral vector into the lumen of a coronary artery of the heart of the
subject by percutaneous intracoronary gene transfer, wherein said viral vector is an adeno-associated viral vector (AAV) comprising
a nucleic acid sequence encoding a polypeptide consisting of amino acids 1-65 of SEQ ID NO: 2, wherein threonine at position
35 of SEQ ID NO: 2 is replaced with an aspartic acid; and wherein said nucleic acid sequence is operably linked to a promoter
capable of directing expression in the heart;

thereby expressing the fragment in the heart of the subject in an amount effective to increase cardiac contractility and reduce
morphological deterioration associated with cardiac remodeling in the subject with existing heart failure.

US Pat. No. 9,569,863

SYSTEM FOR ACCELERATED SEGMENTED MR IMAGE DATA ACQUISITION

Siemens Healthcare GmbH, ...

1. A system for accelerated segmented magnetic resonance (MR) image data acquisition, comprising:
an RF (Radio Frequency) signal generator for generating RF excitation pulses in anatomy and enabling subsequent acquisition
of associated RF echo data; and

a magnetic field gradient generator for generating magnetic field gradients for anatomical volume selection, phase encoding,
and readout RF data acquisition in a three dimensional (3D) anatomical volume,

wherein said RF signal generator and said magnetic field gradient generator are configured to acquire temporally consecutive
segments of k-space line data representative of a first individual image slice in a gradient echo method by adaptively varying
an RF excitation pulse flip angle between acquisition of the temporally consecutive segments before acquiring temporally consecutive
segments of k-space line data representative of a second individual image slice, and

wherein the adaptive variation of the RF excitation pulse flip angles is calculated to provide an equal magnetization across
segments.

US Pat. No. 9,403,815

COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS

The Regents of the Univer...

1. A compound having a structure corresponding to Formula (I):
(A)-(B)-(C)-(D)  (I)
or a pharmaceutically acceptable salt or prodrug thereof:
Wherein A is:

Wherein each E is independently N, NR, C, or CR1 , provided that two or three E's are N or NR;

N is nitrogen; C is carbon; R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted
cycloalkyl, or substituted or unsubstituted aryl;

Each R1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted cycloalkyl,
or substituted or unsubstituted aryl;

Wherein B is:

Wherein each G is independently CR2;

Each R2 is independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamido, substituted or unsubstituted
alkylamino, substituted or unsubstituted amino, substituted or unsubstituted alkylsulfide, substituted or unsubstituted alkyl
sulfinyl group, or substituted or unsubstituted alkyl sulfonyl group;

Wherein B is:

Wherein each G is independently CR3a;

Each R3a is independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamido, substituted or unsubstituted
alkylamino, substituted or unsubstituted amino, substituted or unsubstituted alkylsulfide, substituted or unsubstituted alkyl
sulfinyl group, or substituted or unsubstituted alkyl sulfonyl group;


Wherein each G is independently CR3b;

Each R3b is independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamido, substituted or unsubstituted
alkylamino, substituted or unsubstituted amino, substituted or unsubstituted alkylsulfide, substituted or unsubstituted alkyl
sulfinyl group, or substituted or unsubstituted alkyl sulfonyl group; or


Wherein each G is independently CR3c;

Each R3c is independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamido, substituted or unsubstituted
alkylamino, substituted or unsubstituted amino, substituted or unsubstituted alkylsulfide, substituted or unsubstituted alkyl
sulfinyl group, or substituted or unsubstituted alkyl sulfonyl group; and

Wherein C is:

Wherein R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted
aryl, or substituted or unsubstituted alkoxy; and

Wherein D is:

Wherein R5 is a hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl;

R6a and R6b are independently a hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl;


Wherein R7 is a hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl;

M is independently CHR8;

Each R8 is independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, or substituted or unsubstituted alkoxy; or


Where R9 is a hydrogen, halogen, or a substituted or unsubstituted alkyl;

J is independently CH or N;
Z is independently CHR10;

Each R10 is independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkynyl, or substituted or unsubstituted alkoxy.

US Pat. No. 9,371,277

BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE

Northwestern University, ...

1. A compound selected from compounds of a formula
wherein each of R1 and R2 is independently selected from phenyl, benzyl, heteroaryl, and heteroarylalkyl moieties; each of E1 and E2 is independently selected from CH and N, provided at least one of E1 and E2 is CH; A is a divalent moiety selected from carbonyl, amino, carboxamido (—C(O)NH—), imidocarbyl (—C(NH)—) and a tautomer
thereof (—N ?C(NH2)—) with X; X is a divalent moiety selected from methylene, carbonyl, amino, and aza-substituted ethylene (—NHCH2—) moieties; Y is a divalent moiety selected from oxy, amino, alkylene, and aza-substituted alkylene moieties; and Z is a
divalent moiety selected from sulfonyl, sulfinyl, thio, oxy, amino, and methylene moieties, providing where A is carbonyl,
Z is sulfonyl and R1 and R2 are selected from phenyl and substituted phenyl, X is not amino or methylamino and Y is not amino, alkylamino, allylamino
or benzylamino, and wherein each of R1, R2, A, X, Y and Z is optionally substituted with 1-10 substituents independently selected from halo, cyano, nitro, hydroxy,
amino, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, alkoxy, alkenyl, haloalkyl, aminoalkyl, hydroxyalkyl, alkylene,
alkylsulfonyl, haloalkylsulfonyl, haloalkylsulfinyl, alkylamido, alkylsulfonamido, alkylthio, alkylcarbonyl, alkoxycarbonyl
and combinations of such substituents; R3 is selected from said substituents and combinations thereof; and n is an integer from 0-4, and salts of said compounds.

US Pat. No. 9,301,940

METHODS FOR SCREENING ANTIMICROBIAL AND ANTIVIRAL COMPOUNDS AND USES THEREOF

The General Hospital Corp...

1. A method of treating a Gram-positive bacterial infection in a subject in need thereof, said method comprising administering
to said subject a pharmaceutical composition comprising a compound of formula III:

or a salt thereof, and a pharmaceutically acceptable excipient, wherein
each of R3A, R3B, and R3C is, independently, selected from H, halide, nitro, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OR3G, OC(O)R3H, NR3IR3J, NHC(O)R3K, NHC(S)R3L, NHC(O)OR3M, NHC(S)OR3N, NHC(O)NHR3O, NHC(S)NHR3P, NHC(O)SR3Q, NHC(S)SR3R, NHS(O)2R3S, C(O)OR3T, and C(O)NHR3U;

X3 is independently selected from OR3G, OC(O)R3H, NR3IR3J, NHC(O)R3K, NHC(S)R3L, NHC(O)OR3M, NHC(S)OR3N, NHC(O)NHR3O, NHC(S)NHR3P, NHC(O)SR3Q, NHC(S)SR3R, and NHS(O)2R3S; and

each of R3G, R3H, R3I, R3J, R3K, R3L, R3M, R3N, R3O, R3P, R3Q, R3R, R3S, R3T, and R3U is, independently, selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-6 heterocyclyl, C6-12 aryl, C7-14 alkaryl, C3-10 alkheterocyclyl, and C1-4 heteroalkyl,

wherein said pharmaceutical composition is administered in an amount effective to treat said Gram-positive bacterial infection
and wherein said Gram-positive bacterial infection is selected from the group consisting of community-acquired pneumonia,
upper and lower respiratory tract infection, skin and soft tissue infection, bone and joint infection, hospital-acquired lung
infection, acute bacterial otitis media, bacterial pneumonia, complicated infection, noncomplicated infection, pyelonephritis,
intra-abdominal infection, deep-seated abscess, central nervous system infection, wound infection, peritonitis, meningitis,
infections after burn, urogenital tract infection, gastro-intestinal tract infection, pelvic inflammatory disease, endocarditis,
and intravascular infection.

US Pat. No. 9,115,053

ACTIVATORS OF CLASS I HISTONE DEACETLYASES (HDACS) AND USES THEREOF

Massachusetts Institute o...

1. A compound of Formula (C-VII):
or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein:
each instance of RC1 and RC2 is independently selected from the group consisting of halogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, —ORC2a, —N(RC2b)2, —SRC2a, —C(?O)RC2a, —C(?O)ORC2a, —C(?O)SRC2a, —C(?O)N(RC2b)2, —OC(?O)RC2a, —OC(?O)ORC2a, —OC(?O)SRC2a, —OC(?O)N(RC2b)2, —NRC2bC(?O)RC2b, —NRC2bC(?O)ORC2a, —NRC2bC(?O)SRC2a, —NRC2bC(?O)N(RC2b)2, —SC(?O)RC2a, —SC(?O)ORC2a, —SC(?O)SRC2a, —SC(?O)N(RC2b)2, —C(?NRC2b)RC2a, —C(?NRC2b)ORC2a, —C(?NRC2b)SRC2a, —C(?NRC2b)N(RC2b)2, —OC(?NRC2b)RC2a, —OC(?NRC2b)ORC2a, —OC(?NRC2b)SRC2a, —OC(?NRC2b)N(RC2b)2, —NRC2bC(?NRC2b)RC2b, —NRC2bC(?NRC2b)ORC2a, —NRC2bC(?NRC2b)SRC2a, —NRC2bC(?NRC2b)N(RC2b)2, —SC(?NRC2b)RC2a, —SC(?NRC2b)ORC2a, —SC(?NRC2b)SRC2a, —SC(?NRC2b)N(RC2b)2, —C(?S)RC2a, —C(?S)ORC2a, —C(?S)SRC2a, —C(?S)N(RC2b)2, —OC(?S)RC2a, —OC(?S)ORC2a, —OC(?S)SRC2a, —OC(?S)N(RC2b)2, —NRC2bC(?S)RC2b, —NRC2bC(?S)ORC2a, —NRC2bC(?S)SRC2a, —NRC2bC(?S)N(RC2b)2, —SC(?S)RC2a, —SC(?S)ORC2a, —SC(?S)SRC2a, —SC(?S)N(RC2b)2, —S(?O)RC2a, —SO2RC2a, —NRC2bSO2RC2a, —SO2N(RC2b)2, —CN, —SCN, and —NO2, wherein each occurrence of RC2a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl,
and each occurrence of RC2b is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl,
or a nitrogen protecting group, or two RC2b groups are joined to form an optionally substituted heterocyclic ring;

q is 0, 1, 2, 3, or 4; and
v is 0, 1, 2, or 3;
provided that the compound is not of the formula:
or a pharmaceutically acceptable salt thereof.
US Pat. No. 9,745,261

INHIBITORS OF THE MITF MOLECULAR PATHWAY

THE GENERAL HOSPITAL CORP...

1. A method for treating cancer, comprising administering a therapeutically effective amount of 4-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)benzenesulfonamide
to a subject in need thereof, wherein treatment is inhibiting, slowing down or stopping progression of cancer, and wherein
the cancer is a MITF-dependent cancer.

US Pat. No. 9,498,320

BIOMIMETIC VASCULAR NETWORK AND DEVICES USING THE SAME

THE GENERAL HOSPITAL CORP...

1. An artificial vascular layer comprising:
a substrate defining a network of channels arranged in a pattern having at least one input channel, at least one output channel,
and a plurality of intermediate channels connecting the at least one input channel and the at least one output channel, each
channel having a height, a length, a width, and a diameter, wherein the intermediate channels undergo multiple branching and
rejoining to form hexagonal areas intermediate to the intermediate channels,

wherein the intermediate channels are formed by varying said height and width with respect to adjacent portions of the channels
and the length of a smallest of the intermediate channels is formed based on the respective diameter whereby said smallest
intermediate channel has a biomimetic length.

US Pat. No. 9,447,470

TUMOR GRADING AND CANCER PROGNOSIS

bioTheranostics, Inc., S...

1. A method of predicting responsiveness of a breast cancer afflicted subject to chemotherapy, the method comprising:
obtaining a sample of breast cancer cells from the subject;
assaying a sample of breast cancer cells from the subject for mRNA expression levels of fewer than 97 genes, including Bub1B
and at least one of NEK2, RACGAPI, and RRM2, by producing cDNA from mRNA of the fewer than 97 genes and detecting the cDNA
to determine normalized expression levels of the fewer than 97 genes;

combining the normalized expression levels as a single index into a subject's index using coefficients determined from principle
component analysis;

comparing the subject's index with an index from data from breast cancer tissue in a representative dataset comprising normalized
expression levels of fewer than 97 genes, including Bub1B and at least one of NEK2, RACGAPI, and RRM2 from patients that were
responsive to chemotherapy and breast cancer patients that were not responsive to chemotherapy; and

wherein the cancer of the subject is not likely to be responsive if the subject's index is below a predetermined cutoff value
determined from the index from data of breast cancer tissue from the representative dataset, and the cancer of the subject
is likely to be responsive if the subject's index is above the predetermined cutoff value; and treating the subject with paclitaxel
followed by 5-fluorouracil, doxorubicin and cyclophosphamide (paclitaxel/FAC), taxol or anthracyclin therapy if the method
predicts responsiveness, and treating the subject with surgery or radiation if the method does not predict responsiveness.

US Pat. No. 9,144,594

CATHEPSIN L MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS

University of Miami, Mia...

1. A method of treating proteinuric kidney disease associated with cytosolic cathepsin L activity, comprising:
administering to a patient having proteinuric kidney disease associated with cytosolic cathepsin L activity a therapeutically
effective amount of a small molecule inhibitor of cytosolic cathepsin L activity to treat the proteinuric kidney disease,

wherein the small molecule inhibitor of cytosolic cathepsin L activity is selected from the group consisting of: E-64, E-64a,
E-64b, E-64c, E-64d, CA-074, CA-074 Me, CA-030, CA-028, Z-Phe-Phe-FMK, H-Arg-Lys-Leu-Trp-NH2, N-(1-Naphthalenylsulfonyl)-Ile-Trp-aldehyde,
Z-Phe-Tyr(tBu)-diazomethylketone, Z-Phe-Tyr-aldehyde, and combinations thereof.

US Pat. No. 9,597,347

COMPOSITIONS FOR TREATING OBESITY AND INSULIN RESISTANCE DISORDERS

President and Fellows of ...

1. A method for treating an insulin resistance disorder in a subject in need thereof, comprising administering to the subject
nicotinamide riboside or a nicotinamide riboside analog represented by formula A:

wherein R represents independently for each occurrence H, acetyl, benzoyl, acyl, phosphate, sulfate, (alkyoxy)methyl, triarylmethyl,
(trialkyl)silyl, (dialkyl)(aryl)silyl,

(alkyl)(diaryl)silyl, or (triaryl)silyl; and X represents 0 or S, at a concentration of 1 nM to 10 ?M,
wherein the subject is a human subject.
US Pat. No. 9,329,190

ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY

The General Hospital Corp...

1. A method for determining a level of bioavailable vitamin D and a level of free vitamin D in a subject, the method comprising:
performing assays on a blood sample obtained from the subject to determine a level of VDBP (vitamin D binding protein) polypeptide,
albumin polypeptide and total vitamin D;

calculating a level of bioavailable vitamin D, wherein a level of bioavailable vitamin D is:
=(Kalb*[Alb]+1)*[Free Vitamin D]
and calculating a level of free vitamin D, wherein a level of free vitamin D is:
={?{KDBP·[Total DBP]?KDBP·[Total Vitamin D]+Kalb·[Alb]+1}+?{(KDBP·[Total DBP]?KDBP·[Total Vitamin D]+Kalb·[Alb]+1)2+4·(KDBP·Kalb·[Alb]+KDBP)·([Total Vitamin D])}}÷(2·{KDBP·Kalb·[Alb]+KDBP}).

US Pat. No. 9,241,928

ANTIMICROBIAL COMPOUNDS

The General Hospital Corp...

1. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and

US Pat. No. 9,555,072

VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

The General Hospital Corp...

1. A method of treating cancer of the nervous system in a patient, said method comprising administering to a patient having
cancer of the nervous system a herpes simplex virus-1, wherein said herpes simplex virus-1 comprises:
an inactivating mutation in the ICP47 locus of said virus, wherein said mutation occurs between the BstEII site and the EcoNI
site of the BamHI fragment encompassing the ICP47 region, and said mutation places US11 under control of the ICP47 immediate-early
promoter that results in early expression of US11;

an inactivating mutation in the ?34.5 neurovirulence locus of said virus; and
an inactivating mutation in the ICP6 locus of said virus.

US Pat. No. 10,067,211

SYSTEM AND METHOD FOR ESTIMATING PHASE MEASUREMENTS IN MAGNETIC RESONANCE IMAGING

The General Hospital Corp...

1. A method for estimating a phase of a magnetic resonance signal using a magnetic resonance imaging (MRI) system, the steps of the method comprising:a) determining with a computer system at least two echo time spacings that define a duration of time between pairs of echo times, the at least two echo time spacings being determined by optimizing phase ambiguity functions that are associated with the at least two echo time spacings;
b) acquiring data by directing a radio frequency (RF) system and a gradient system of the MRI system to perform a pulse sequence that includes forming echoes at a plurality of echo times that are spaced apart in time using the determined at least two echo time spacings; and
c) estimating with a data processing server of the MRI system a phase value at each voxel location in an image matrix using the acquired data and the determined at least two echo time spacings.

US Pat. No. 9,944,931

METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS

Dana-Farber Cancer Instit...

1. An immunoresponsive cell having tumor specificity comprising a vector, the vector comprising a sequence encoding a shRNA,wherein the shRNA comprises 15 contiguous nucleotides complementary to a nucleic acid sequence of SEQ ID NO: 604.
US Pat. No. 9,052,308

ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY

The General Hospital Corp...

1. A method for treating a Vitamin D insufficiency in a subject, the method comprising:
determining a level of bioavailable Vitamin D in the subject by directly detecting levels of free Vitamin D and Vitamin D
bound to albumin in a sample comprising serum or plasma from the subject using a differential affinity precipitation assay;

detecting the presence of a vitamin D binding protein variant genotype in the subject, comparing the level of bioavailable
Vitamin D in the sample to a genotype-specific reference level of Vitamin D;

identifying a subject who has a level of bioavailable Vitamin D below the reference level of Vitamin D as having a Vitamin
D insufficiency; and

administering a vitamin D insufficiency treatment to a subject identified as having a vitamin D insufficiency.

US Pat. No. 9,657,329

PROPEPTIDE-LUCIFERASE FUSION PROTEINS AND METHODS OF USE THEREOF

The Broad Institute Inc.,...

1. A nucleic acid construct comprising a nucleic acid molecule comprising a sequence encoding a propeptide-bioluminescent
fusion protein for expression in a cell
wherein:
the propeptide is a precursor to a mature peptide and the mature peptide is secreted or expressed at the cell surface,
the propeptide-bioluminescent fusion protein comprises the bioluminescent protein and the propeptide wherein the bioluminescent
protein is inserted into the propeptide,

the bioluminescent protein comprises two cleavage sites, the first of which is positioned no more than four amino acids from
the N-terminal end of the bioluminescent protein and the second of which is positioned no more than four amino acids from
the C-terminal end of the bioluminescent protein, and

when the propeptide-bioluminescent fusion protein is expressed by the cell, the bioluminescent protein is cleaved from the
propeptide and the bioluminescent protein is secreted simultaneously with the secretion of the mature peptide, or

when the bioluminescent-fusion protein is expressed by the cell, the bioluminescent protein is cleaved from the propeptide
simultaneously upon expression of the mature peptide at the cell surface.

US Pat. No. 9,499,488

VITAMIN D RECEPTOR AGONISTS AND USES THEREOF

Beth Israel Deaconess Med...

1. A method for treating a vitamin D receptor-mediated condition in a subject in need thereof, said method comprising administering
to said subject the compound:
or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat said condition, and wherein said condition
is selected from cardiac hypertrophy and hyperparathyroidism.

US Pat. No. 9,308,120

METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING

The General Hospital Corp...

1. A system for removing heat from subcutaneous lipid rich cells of a subject, the system comprising:
a cooling device having a cooling element programmed to reduce a temperature of a local region containing the lipid rich cells
to between about ?10° C. and about 20° C. such that lipid rich cells in the local region are reduced while non-lipid rich
cells in the epidermis are generally not reduced; and

a suction unit coupled to the cooling device to apply vacuum to the local region.
US Pat. No. 9,347,100

RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS

GPB Scientific, LLC, Ric...

1. A computer program product embodied in a non-transitory computer readable medium comprising instructions executable by
one or more processors to cause a system to perform functions to determine a presence or absence of a fetal aneuploidy in
a mixture of fetal and maternal genomic DNA obtained from a maternal blood sample obtained from a woman who is pregnant or
who is suspected of being pregnant, wherein the functions comprise:
receiving genomic DNA sequence data representing a complete genome, wherein the DNA sequence data is obtained by conducting
whole genome amplification of a mixture of fetal and maternal genomic DNA to obtain amplified nucleic acid molecules, and
conducting ultra-deep sequencing of the amplified nucleic acid molecules obtained from the mixture of fetal and maternal genomic
DNA, thereby producing sequence data representing the complete genome, and wherein the ultra-deep sequencing comprises further
amplification of the amplified nucleic acid molecules to produce at least one million copies of individual amplified nucleic
acid molecules in parallel;

processing the DNA sequence data to quantify DNA regions of (i) at least one test chromosome being tested for a presence or
absence of fetal aneuploidy, and (ii) at least one control chromosome that is diploid;

determining the presence or absence of fetal aneuploidy for the at least one test chromosome based on data for the quantified
DNA regions of the at least one test chromosome and the at least one control chromosome;

constructing an image file from the DNA sequence data and
printing or displaying an image from the data in the image file.
US Pat. No. 9,265,766

METHODS FOR ALTERING MRNA SPLICING AND TREATING FAMILIAL DYSAUTONOMIA BY ADMINISTERING BENZYLADENINE

The General Hospital Corp...

1. A method to increase a ratio of wild type IKBKAP mRNA to misspliced IKBKAP mRNA in human cells, wherein said misspliced
IKBKAP mRNA is transcribed from a mutant IKBKAP gene which expresses wild type and misspliced IKBKAP mRNA, which mutant IKBKAP
gene includes the IVS20+6T?C mutation, said method comprising contacting cells possessing said mutant IKBKAP gene with benzyladenine in an amount effective
to increase said ratio of wild type mRNA to misspliced mRNA in said cells.

US Pat. No. 9,178,330

APPARATUS AND METHOD FOR UTILIZATION OF A HIGH-SPEED OPTICAL WAVELENGTH TUNING SOURCE

The General Hospital Corp...

1. An apparatus comprising:
at least one wavelength swept laser arrangement configured to emit an electromagnetic radiation that has a spectrum whose
mean frequency changes (i) at an absolute rate that is greater than about 6000 terahertz per millisecond, and (ii) over a
range that is greater than about 10 terahertz, wherein the spectrum has an instantaneous line width that is smaller than 100
gigahertz.

US Pat. No. 9,282,931

METHODS FOR TISSUE ANALYSIS

The General Hospital Corp...

1. A method of analyzing a tissue structure, comprising:
illuminating the tissue structure with at least one of a coherent light or a partially coherent light from a light source
onto the tissue structure;

receiving a further light reflected from the tissue structure and forming a series of speckle patterns based on the further
light; and

obtaining speckle pattern data from the series of speckle patterns at time intervals sufficient to measure a microscopic motion
within the tissue structure or within a tissue adjacent to the structure; and

assessing the tissue structure by analyzing spatial characteristics of the speckle pattern data, and determining at least
one of structural characteristics or biomechanical characteristics of the tissue structure which is in vivo tissue based on
the assessment of the tissue structure.

US Pat. No. 9,492,508

PARATHYROID HORMONE ANALOGS AND USES THEREOF

The General Hospital Corp...


X01 is Ser or Ala;

X03 is Ser, Ala, or Aib;

X08 is Met, Leu, or Nle;

X10 is Asn or Gln;

X11 is Leu, Arg, or Har;

X12 is Gly or Ala;

X13 is Lys;

X14 is His or Trp;

X15 is Ile;

X16 is Gln;

X17 is Asp;

X18 is Ala;

X22 is Ala;

X25 is His; and

X26 is Lys;

or a pharmaceutically acceptable salt thereof.
US Pat. No. 9,150,860

FUS/TLS-BASED COMPOUNDS AND METHODS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED MOTOR NEURON DISEASES

The General Hospital Corp...

1. A method for detecting a mutant FUS/TLS gene in a human subject, comprising:
(a) direct sequencing a FUS/TLS nucleic acid as set forth in SEQ ID NO:3 or a fragment thereof in a sample obtained from a
human subject, and

(b) detecting a genetic variant in the FUS/TLS nucleic acid, wherein said genetic variant is selected from: a G at the position
corresponding to position 1551 of SEQ ID NO:3; a G at the position corresponding to position 1561 of SEQ ID NO:3; a Tat the
position corresponding to position 1542 of SEQ ID NO:3; a T at the position corresponding to position 1543 of SEQ ID NO:3;
a T at the position corresponding to position 1561 of SEQ ID NO:3; an A at the position corresponding to position 1562 of
SEQ ID NO:3; a G at the position corresponding to position 1564 of SEQ ID NO: 3; and a C at the position corresponding to
position 1572 of SEQ ID NO:3.

US Pat. No. 10,231,820

FABRICATION OF VASCULARIZED TISSUE USING MICROFABRICATED TWO-DIMENSIONAL MOLDS

The Charles Stark Draper ...

1. A lamina assembly comprising:a lower structure having an upper side defining lower structure channels;
an upper structure having a lower side defining at least one upper structure microchannel that opposes the lower structure channels;
a semi-permeable membrane disposed between the lower and upper structures to separate the respective channels; and
cells cultured on at least one side of the semi-permeable membrane.

US Pat. No. 9,304,121

METHOD AND APPARATUS FOR OPTICAL IMAGING VIA SPECTRAL ENCODING

The General Hospital Corp...

1. An apparatus comprising:
at least one probe arrangement configured to forward an electromagnetic radiation to an anatomical structure, and continuously
scan an entire region of at least one portion of the anatomical structure using the electromagnetic radiation to generate
at least one signal, wherein the at least one probe arrangement includes at least one housing, at least one optical moving
section and at least one force applying section provided within the at least one housing, and wherein the force applying section
includes an elastic arrangement, and applies a force on the at least one optical moving section to be in contact with the
at least one housing.

US Pat. No. 9,243,221

COMPOSITIONS AND METHODS OF FUNCTIONALLY ENHANCED IN VITRO CELL CULTURE SYSTEM

HUREL CORPORATION, Bever...

1. A cell culture system, comprising:
a) a cell culture compartment comprising a cell culture substrate and a cell culture medium comprising no more than about
10% serum;

b) a coculture of metabolically active primary hepatocytes and at least one other cell type, said coculture seeded onto the
culture substrate and cultured in the culture medium; and

c) a gaseous composition in contact with the culture medium and comprising at least about 90% oxygen.

US Pat. No. 9,273,189

HIGHLY CRYSTALLINE POLYETHYLENE

The General Hospital Corp...

1. A method of making a cross-linked and interlocked hybrid material for a medical device or implant, wherein the method comprises:
a) mixing a polymeric material with an antioxidant to form a polymeric blend;
b) compression molding of the polymeric blend to the counterface of second material, thereby forming an interlocked hybrid
material having an interface between the polymeric blend and the second material;

c) elevating the temperature of the interlocked hybrid material to about 80° C. to below the melting point of the polymeric
blend; and

d) irradiating the interlocked hybrid material from step (c) by electron beam radiation at the elevated temperature that is
between about 80° C. to below the melting point of the polymeric blend, thereby forming cross-links in the polymeric blend
and yielding a cross-linked and interlocked hybrid material for a medical device or implant, wherein: (i) the cross-linking
strengthens the polymeric blend to minimize separation at the interface, (ii) the antioxidant provides resistance to post-irradiation
oxidation, and (iii) the irradiation sterilizes the interface.

US Pat. No. 10,137,122

KINASE INHIBITORS AND METHODS OF USE THEREOF

The Broad Institute, Inc....

1. A method of treating Fragile X syndrome comprising administering to a subject suffering from Fragile X syndrome an effective amount of a compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl;
R2 is unsubstituted C1-6 aliphatic or C1-6 aliphatic substituted with one or more instances of halogen;
or R1 and R2 are taken together with their intervening atoms to form optionally substituted, 3- to 7-membered, monocyclic, saturated, carbocyclyl or heterocyclyl, wherein the carbocyclyl or heterocyclyl formed by taking together R1 and R2 is optionally fused to optionally substituted phenyl or optionally substituted heteroaryl;
R3 is selected from the group consisting of hydrogen, halogen, —CN, —NO2, optionally substituted C1-6 aliphatic, —ORA, —N(RB)2, and —SRA;
each RA is independently selected from the group consisting of hydrogen and optionally substituted C1-6 aliphatic;
each RB is independently selected from the group consisting of hydrogen and optionally substituted C1-6 aliphatic;
R4a and R4b are each hydrogen;
R5a and R5b are each independently selected from the group consisting of hydrogen, halogen, —CN, —ORA, —N(RB)2, unsubstituted C1-6 aliphatic, and C1-6 aliphatic substituted with one or more instances of halogen, or R5a and R5b are taken together with their intervening atoms to form unsubstituted, 3- to 7-membered, monocyclic, saturated, carbocyclyl or heterocyclyl; and
R6a and R6b are each hydrogen;
wherein:
each instance of the heteroaryl is independently 5- or 6-membered, monocyclic heteroaryl comprising 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, as valency allows;
each instance of the heterocyclyl independently comprises 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, as valency allows;
when any one of the aliphatic, carbocyclyl, heterocyclyl, phenyl, and heteroaryl referred to above is substituted with one or more substituents at a carbon atom, the one or more substituents at the carbon atom are independently selected from Group (i);
when any one of the heterocyclyl and heteroaryl referred to above is substituted with one or more substituents at a nitrogen atoms, the one or more substituents at the nitrogen atom are independently selected from Group (ii);
Group (i) consists of halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —ORaa, —ON(Rbb)2, —N(Rbb)2, —N(Rbb)3+X?, —N(ORcc)Rbb, —SH, —SRaa, —SSRcc, —C(?O)Raa, —CO2H, —CHO, —C(ORcc)2, —CO2Raa, —OC(?O)Raa, —OCO2Raa, —C(?O)N(Rbb)2, —OC(?O)N(Rbb)2, —NRbbC(?O)Raa, —NRbbCO2Raa, —NRbbC(?O)N(Rbb)2, —C(?NRbb)Raa, —C(?NRbb)ORaa, —OC(?NRbb)Raa, —OC(?NRbb)ORaa, —C(?NRbb)N(Rbb)2, —OC(?NRbb)N(Rbb)2, —NRbbC(?NRbb)N(Rbb)2, —C(?O)NRbbSO2Raa, —NRbbSO2Raa, —SO2N(Rbb)2, —SO2Raa, —SO2ORaa, —OSO2Raa, —S(?O)Raa, —OS(?O)Raa, —Si(Raa)3, —OSi(Raa)3—C(?S)N(Rbb)2, —C(?O)SRaa, —C(?S)SRaa, —SC(?S)SRaa, —SC(?O)SRaa, —OC(?O)SRaa, —SC(?O)ORaa, —SC(?O)Raa, —P(?O)(Raa)2, —OP(?O)(Raa)2, —OP(?O)(ORcc)2, —P(?O)(NRbb)2, —OP(?O)(NRbb)2, —NRbbP(?O)(ORcc)2, —NRbbP(?O)(NRbb)2, —P(Rcc)2, —OP(Rcc)2, —B(Raa)2, —B(ORcc)2, —BRaa(ORcc), C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups; or two geminal hydrogens on a carbon atom are replaced with the group ?O, ?S, ?NN(Rbb)2, ?NNRbbC(?O)Raa, ?NNRbbC(?O)ORaa, ?NNRbbS(?O)2Raa, ?NRbb, or ?NORcc; and
Group (ii) consists of hydrogen, —OH, —ORaa, —N(Rcc)2, —CN, —C(?O)Raa, —C(?O)N(Rcc)2, —CO2Raa, —SO2Raa, —C(?NRbb)Raa, —C(?NRcc)ORaa, —C(?NRcc)N(Rcc)2, —SO2N(Rcc)2, —SO2Rcc, —SO2ORcc, —SORaa, —C(?S)N(Rcc)2, —C(?O)SRcc, —C(?S)SRcc, —P(?O)(Raa)2, —P(?O)(NRcc)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
wherein:
each instance of Raa is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Raa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
each instance of Rbb is, independently, selected from hydrogen, —OH, —ORaa, —N(Rcc)2, —CN, —C(?O)Raa, —C(?O)N(Rcc)2, —CO2Raa, —SO2Raa, —C(?NRcc)ORaa, —C(?NRcc)N(Rcc)2, —SO2N(Rcc)2, —SO2Rcc, —SO2OR, —SORaa, —C(?S)N(Rcc)2, —C(?O)SRcc, —C(?S)SRcc, —P(?O)(Raa)2, —P(?O)(NRcc)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Rbb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
each instance of Rcc is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Rcc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
each instance of Rdd is, independently, selected from halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —ORee, —ON(Rff)2, —N(Rff)2, —N(Rff)3+X?, —N(ORee)Rff, —SH, —SRee, —SSRee, —C(?O)Ree, —CO2H, —CO2Ree, —OC(?O)Ree, —OCO2Ree, —C(?O)N(Rff)2, —OC(?O)N(Rff)2, —NRffC(?O)Ree, —NRffCO2Ree, —NRffC(?O)N(Rff)2, —C(?NRff)ORee, —OC(?NRff)Ree, —OC(?NRff)ORee, —C(?NRff)N(Rff)2, —OC(?NRff)N(Rff)2, —NRffC(?NRff)N(Rff)2, —NRffSO2Ree, —SO2N(Rff)2, —SO2Ree, —SO2ORee, —OSO2Ree, —S(?O)Ree, —Si(Ree)3, —OSi(Ree)3, —C(?S)N(Rff)2, —C(?O)SRee, —C(?S)SRee, —SC(?S)SRee, —P(?O)(Ree)2, —OP(?O)(Ree)2, —OP(?O)(ORee)2, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, 3-10 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups, or two geminal Rdd substituents can be joined to form ?O or ?S;
each instance of Ree is, independently, selected from C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups;
each instance of Rff is, independently, selected from hydrogen, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, 3-10 membered heterocyclyl, C6-10 aryl and 5-10 membered heteroaryl, or two Rff groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups;
each instance of Rgg is, independently, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —OC1-6 alkyl, —ON(C1-6 alkyl)2, —N(C1-6 alkyl)2, —N(C1-6 alkyl)3+X?, —NH(C1-6 alkyl)2+X?, —NH2(C1-6 alkyl)+X?, —NH3+X?, —N(OC1-6 alkyl)(C1-6 alkyl), —N(OH)(C1-6 alkyl), —NH(OH), —SH, —SC1-6 alkyl, —SS(C1-6 alkyl), —C(?O)(C1-6 alkyl), —CO2H, —CO2(C1-6 alkyl), —OC(?O)(C1-6 alkyl), —OCO2(C1-6 alkyl), —C(?O)NH2, —C(?O)N(C1-6 alkyl)2, —OC(?O)NH(C1-6 alkyl), —NHC(?O)(C1-6 alkyl), —N(C1-6 alkyl)C(?O)(C1-6 alkyl), —NHCO2(C1-6 alkyl), —NHC(?O)N(C1-6 alkyl)2, —NHC(?O)NH(C1-6 alkyl), —NHC(?O)NH2, —C(?NH)O(C1-6 alkyl), —OC(?NH)(C1-6 alkyl), —OC(?NH)OC1-6 alkyl, —C(?NH)N(C1-6 alkyl)2, —C(?NH)NH(C1-6 alkyl), —C(?NH)NH2, —OC(?NH)N(C1-6 alkyl)2, —OC(NH)NH(C1-6 alkyl), —OC(NH)NH2, —NHC(NH)N(C1-6 alkyl)2, —NHC(?NH)NH2, —NHSO2(C1-6 alkyl), —SO2N(C1-6 alkyl)2, —SO2NH(C1-6 alkyl), —SO2NH2, —SO2C1-6 alkyl, —SO2OC1-6 alkyl, —OSO2C1-6 alkyl, —SOC1-6 alkyl, —Si(C1-6 alkyl)3, —OSi(C1-6 alkyl)3 —C(?S)N(C1-6 alkyl)2, C(?S)NH(C1-6 alkyl), C(?S)NH2, —C(?O)S(C1-6 alkyl), —C(?S)SC1-6 alkyl, —SC(?S)SC1-6 alkyl, —P(?O)(C1-6 alkyl)2, —OP(?O)(C1-6 alkyl)2, —OP(?)(OC1-6 alkyl)2, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal Rgg substituents can be joined to form ?O or ?S; and
X? is a counterion, wherein the counterion is a halide ion, NO3?, ClO4?, OH?, H2PO4?, HSO4?, a sulfonate ion, or a carboxylate ion.

US Pat. No. 9,365,498

INHIBITORS OF HISTONE DEACETYLASE

The Broad Institute, Inc....

1. A compound having formula I:
or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein:
the moiety

 is of the formula:

U is selected from single bond and NR2d;

V is selected from C and N, provided that when V is N, one of R2a, R2b, or R2c is absent;

each X is independently selected from hydrogen, deuterium, methyl, CF3, and halogen;

R2a is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl;

R2b is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl;

R2c is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl;

R2d is selected from NH2 and C1-C8 alkyl;

provided that:
taken together two of R2a, R2b, and R2c form a C3-C8 cycloalkyl ring, C4-C8 cycloalkenyl ring, or 3 to 8 membered saturated or partially unsaturated heterocyclic ring containing 1, 2, 3, or 4 nitrogen
atoms, and the remaining R2a, R2b, or R2c is absent or selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl, further wherein:

said cycloalkyl ring formed by taking together two of R2a, R2b, and R2c is substituted with two or more Rx, wherein two Rx are taken together to form a C3-C8 cycloalkyl ring that is substituted with one or more Rz or is unsubstituted, C4-C8 cycloalkenyl ring, or 3 to 8 membered saturated or partially unsaturated heterocyclic ring, further wherein said cycloalkenyl
ring and heterocyclic ring are unsubstituted or substituted with one or more Rz, or to form an aromatic ring or heteroaromatic ring, further wherein said aromatic ring and heteroaromatic ring are monocyclic
or bicyclic, and are unsubstituted or substituted with one or more Rz; and

said cycloalkenyl ring formed by taking together two of R2a, R2b, and R2c, and heterocyclic ring formed by taking together two of R2a, R2b, and R2c are unsubstituted or substituted with one or more Rx;

or taken together R2d and one of R2a, R2b,and R2c form a 3 to 8 membered saturated or partially unsaturated heterocyclic ring, and: the remaining R2a, R2b, or R2c is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl, or taken together two of the remaining R2a, R2b, and R2c form ?O; further wherein said heterocyclic ring is unsubstituted or substituted with one or more Rx;

or taken together two of R2a, R2b, and R2c form an aromatic or heteroaromatic ring and the remaining R2a, R2b, or R2c is absent, provided that when two of R2a, R2b,and R2c form an aromatic or heteroaromatic ring and the remaining R2a, R2b, or R2c is absent, U is not a single bond, further wherein: said aromatic ring is monocyclic, bicyclic, or tricyclic, and is unsubstituted
or substituted with one or more Rx; and said heteroaromatic ring is monocyclic or bicyclic, and is unsubstituted or substituted with one or more Rx;

each Rx is independently selected from (CH2)zNH2, (CH2)zNHR3, (CH2)zNR3R3, OR3, OCF3, OCH2F, OCHF2, (CH2)z-aromatic ring, (CH2)z-heterocyclic ring, hydroxyl, halogen, C1-C8 alkyl, (C1-C8 alkyl)CF3, (C1-C8 alkyl)OH, C(O)R3?(CH2)zC(O)NH2, (CH2)zC(O)NHR3, (CH2)zC(O)NR3R3, (CH2)zNHC(O)R4, and (CH2)zNR4C(O)R4; wherein the aromatic ring is monocyclic, bicyclic, or tricyclic, and the heterocyclic ring is 3 or 8 membered;

or taken together two Rx attached to the same carbon atom of a cycloalkyl, cycloalkenyl or heterocyclic ring form ?O;

or taken together two Rx form a C3-C8 cycloalkyl ring, C4-C8 cycloalkenyl ring, or 3 to 8 membered saturated or partially unsaturated heterocyclic ring, further wherein said cycloalkyl
ring cycloalkenyl ring, and heterocyclic ring are unsubstituted or substituted with one or more Rz;

or taken together two Rx form an aromatic ring or heteroaromatic ring, further wherein: said aromatic ring is monocyclic, bicyclic, or tricyclic, and
is unsubstituted or substituted with one or more Rz; and said heteroaromatic ring is monocyclic or bicyclic, and is unsubstituted or substituted with one or more Rz;

each Rz is independently selected from halogen, C1-C4 alkyl, OH, OR3, CF3, OCF3, OCH2F, OCHF2, NH2, NHR3, NR3R3, and C(O)CH3;

R3 is C1-C8 alkyl;

R4 is selected from C1-C8 alkyl and CF3;

R5 is selected from hydrogen, deuterium, halogen, OH, OCH3, CF3, CH3, and cyclopropyl;

t is selected from 0, 1, and
z is selected from 0, 1, 2, and 3.

US Pat. No. 9,669,143

SYNCHRONIZED INTRAVENTRICULAR BALLOON ASSISTANCE DEVICE

THE GENERAL HOSPITAL CORP...

1. A method for facilitating a movement of a myocardial wall, the method comprising:
transferring a motion of a ventricular chamber to a first balloon disposed there within, the first balloon containing a fluid;
in response to the transferred motion, forming a flow of the fluid from the first balloon through a tubular connector to a
second balloon juxtaposed with the myocardial wall;

transferring motion of the second balloon defined by the flow of fluid to the myocardial wall.

US Pat. No. 9,226,665

SPECKLE REDUCTION IN OPTICAL COHERENCE TOMOGRAPHY BY PATH LENGTH ENCODED ANGULAR COMPOUNDING

The General Hospital Corp...

1. An apparatus for obtaining information associated with a structure, comprising;
an optical first arrangement including an optical section that is configured to provide a first radiation and a second radiation
that are forwarded to the structure, wherein the first and second radiations have different path lengths;

an interferometer second arrangement configured to receive third and fourth radiations from the structure associated with
the first and second radiations and a fifth radiation received from a reference; and

a computer third arrangement configured to generate the information of images associated with the structure which have different
delays with respect to one another based on the third, fourth and fifth radiations.

US Pat. No. 9,193,783

DRG11-RESPONSIVE (DRAGON) POLYPEPTIDES

The General Hospital Corp...

1. A substantially pure polypeptide comprising a fragment of at least 50 consecutive amino acids of a sequence selected from
the group consisting of SEQ ID NO: 6, 9 and 29, wherein said polypeptide or fragment thereof lacks the C-terminal GPI anchor
domain and is linked to a heterologous sequence.

US Pat. No. 9,283,133

POSITIONING DEVICE FOR USE IN SURGICAL PROCEDURES

The General Hospital Corp...

1. A device to position a patient in a selected body position on an operating table, the device comprising:
a board configured to be placed on and move freely relative to the operating table and sized to support at least the patient's
back when the patient is placed on the device;

shoulder supports engaging the board and extending substantially perpendicular from the board;
a cushioning mat positioned over the board and the shoulder supports so that the cushioning mat is configured to lie between
the patient and the board and the shoulder supports when the patient is placed on the device;

a locking mechanism removably coupling the shoulder supports to the board to allow the cushioning mat to lie substantially
flat when the shoulder supports are decoupled from the board and thereby configured to provide access to a neck and shoulders
of the patient when the patient is placed on the device; and

a coupling mechanism including a rod coupled to each of the shoulder supports and a clamp engaging each rod and configured
to be coupled to the operating table, the coupling mechanism configured to removably affix the shoulder supports to the operating
table as the operating table is rotated about a range of incline and decline positions.

US Pat. No. 9,575,072

DIAGNOSTIC AND THERAPEUTIC USES OF GELSOLIN IN RENAL FAILURE

Beth Israel Deaconess Med...

1. A method for evaluating the efficacy of a therapy in a chronic renal failure subject, the method comprising:
(i) determining a level of plasma gelsolin from the subject,
(ii) comparing the level of plasma gelsolin from the subject to a predetermined value of about 150 ng of gelsolin/?l of plasma,
(iii) determining whether the level of plasma gelsolin is at or above the predetermined value, said determination indicating
that the therapy is efficacious; and

(iv) continuing the therapy in the subject having a level of plasma gelsolin at or above the predetermined value, or discontinuing
or changing the therapy in the subject having a level of plasma gelsolin below the predetermined value.

US Pat. No. 9,415,070

METHODS AND COMPOSITIONS FOR LOCALIZED DELIVERY OF AGENTS TO VIRALLY INFECTED CELLS AND TISSUES

Massachusetts Institute o...

1. A method for delivering IL-15 superagonist (IL-15SA) to Human Immunodeficiency Virus (HIV)-infected cells, including cells
latently infected with HIV, the method comprising
administering, to a subject having or suspected of having an HIV infection, a HIV-specific T cell bound to a nanoparticle
that comprises IL-15SA in an amount effective to induce HIV expression from cells latently infected with HIV, wherein the
agent is released from the nanoparticle in vivo.

US Pat. No. 9,273,355

RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS

The General Hospital Corp...

1. A method for fetal diagnosis comprising:
labeling one or more genomic DNA regions in fetal and non-fetal cells, enriched from a maternal blood sample, wherein said
labels distinguish between individual cells;

splitting said fetal and non-fetal cells such that individual cells are in addressable locations; and
determining the presence or absence of a fetal abnormality by analyzing said labeled genomic DNA regions.

US Pat. No. 9,733,329

SYSTEM AND METHOD FOR FIELD MAP ESTIMATION

The General Hospital Corp...

1. A magnetic resonance imaging (MRI) system comprising:
a magnet system configured to generate a polarizing magnetic field about at least a region of interest (ROI) in a subject
arranged in the MRI system;

a plurality of gradient coils configured to apply a gradient field to the polarizing magnetic field;
a radio frequency (RF) system configured to apply an excitation field to the subject and acquire MR image data from a ROI;
a computer system programmed to:
select a pulse sequence to be performed by the plurality of gradient coils and RF system to elicit at least three echoes from
the subject as medical imaging data;

compute angle locations for different pairs of the at least three echoes and magnetic field map estimates;
replicate the magnetic field map estimates over a dynamic range of interest associated with the pulse sequence;
identify magnetic field map estimates that provide a desired solution to a phase ambiguity function; and
using the magnetic field map estimates that provide the desired solution in order to indicate a magnetic field map solution
based on one of the pair of echoes selected from the at least three echoes; and store the indicated magnetic field map solution
in a memory for later use.

US Pat. No. 9,457,047

IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF

Whitehead Institute, Cam...

1. A composition comprising ?-1-6-glucan linked to a targeting moiety, wherein the targeting moiety is selected from the group
consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule,
and wherein the targeting moiety specifically interacts with a neoplastic cell, a pre-neoplastic cell, a pathogen, or a component
thereof.

US Pat. No. 9,068,181

MICROFLUIDIC DROPLET ENCAPSULATION

The General Hospital Corp...

1. A method of encapsulating particles in liquid droplets, the method comprising
passing a plurality of particles in a fluid medium through a channel having a minimum cross-sectional dimension D, wherein
the largest particle in the plurality has a maximum cross-sectional dimension that is at least about 0.1D;

ordering the plurality of particles into one or two ordered streams of particles in the fluid medium within the channel by
flowing the fluid medium through the channel at a flow rate having a particle Reynolds Number (Rp) of about 2.9 and a Reynolds
Number (Rc) of about 90, wherein ordering of particles occurs within a distance of about 1.0 cm along the channel; and

forming the fluid medium into a plurality of droplets outside the channel, under conditions wherein the proportion of the
plurality of droplets containing only one particle is at least about 80% of the total number of droplets formed outside the
channel.

US Pat. No. 9,856,533

PREDICTING BREAST CANCER TREATMENT OUTCOME

Biotheranostics, Inc., S...

1. A method for treating a human subject having ER+ (estrogen receptor positive) breast cancer, comprising
assaying a breast cancer cell sample from the human subject by determining a ratio of HoxB13 and IL17BR mRNA expression levels
in the breast cancer cell sample;

comparing the ratio of HoxB13 and IL17BR mRNA expression levels in the breast cancer cell sample to a HoxB13 and IL17BR mRNA
expression level threshold ratio,

wherein a ratio of HoxB13 and IL17BR mRNA expression levels above the threshold ratio indicates an outcome comprising cancer
recurrence via metastasis following tamoxifen or letrozole treatment, and

treating the human subject with an alternative therapy other than tamoxifen or letrozole, if the ratio of HoxB13 and IL17BR
mRNA expression levels is above the threshold ratio, wherein the alternative therapy other than tamoxifen or letrozole comprises
a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD), an aromatase inhibitor
(AI), surgical ovarian ablation, or chemical ovarian ablation.

US Pat. No. 9,284,381

METHODS AND REAGENTS FOR PREPARING MULTIFUNCTIONAL PROBES

The General Hospital Corp...

1. A reagent for preparing a multifunctional probe including a substrate, the reagent comprising:
a peptide scaffold having a reactive group suitable for reacting with a complementary reactive group on the substrate;
a first functional group attached to the scaffold; and
a second functional group attached to the scaffold, the second functional group being different from the first functional
group,

wherein the peptide includes 20 or less amino acid residues, and
wherein the first functional group and the second functional group are different from natural side chains of the amino acid
residues of the peptide.

US Pat. No. 10,058,688

MEDICAMENT, METHOD, AND DRUG DELIVERY DEVICE FOR TREATMENT OF OVARIAN CANCER

Massachusetts Institute o...

1. A method of intraperitoneal delivery of drug to a patient comprising:implanting within a peritoneal cavity of the patient an elongated, flexible device which comprises a housing defining a reservoir that contains a drug in solid or semi-solid form, wherein the drug comprises cisplatin;
solubilizing the drug at least in part with peritoneal fluid; and
releasing an effective amount of the solubilized drug from the reservoir into the peritoneal cavity continuously for a period of at least 24 hours.

US Pat. No. 9,738,860

FABRICATION OF VASCULARIZED TISSUE USING MICROFABRICATED TWO-DIMENSIONAL MOLDS

The General Hospital Corp...

1. A tissue lamina assembly comprising:
a lower mold having an upper side defining lower mold microchannels;
an upper mold having a lower side defining upper mold microchannels that oppose the lower mold microchannels;
a semi-permeable membrane disposed between the lower and upper molds to separate the respective microchannels; and
cells cultured on at least one side of the semi-permeable membrane.
US Pat. No. 9,295,662

METHODS FOR ENHANCING, IMPROVING, OR INCREASING FERTILITY OR REPRODUCTIVE FUNCTION

The General Hospital Corp...

1. A method for enhancing, improving, or increasing a female human's likelihood of becoming pregnant comprising:
administering to the human a nutritional, dietary, or food fatty acid supplement comprising:
at least 30% docosahexaenoic acid (DHA), by weight of the total fatty acids in the supplement in a form chosen from ethyl
ester, free fatty acid, and triglyceride.

US Pat. No. 9,733,460

METHOD AND APPARATUS FOR MICROSCOPIC IMAGING

The General Hospital Corp...

1. An apparatus for facilitating a microscopic imaging of at least one anatomical structure, comprising:
a spectrally-encoded confocal microscopy (SECM) system configured to provide at least one first electro-magnetic radiation
to the at least one anatomical structure; and

a mobile device communicating with the SECM system, and including a sensor arrangement that is configured to receive at least
one second electro-magnetic radiation that is based on the at least one first electro-magentic radiation from at least one
section of the SECM system, the mobile device further including a computer arrangement which is configured to display at least
one portion of the at least one anatomical structure as a microscopic image based on the at least one second radiation received
by the sensor arrangement,

wherein the at least one first electro-magnetic radiation is originated from a radiation source residing in the mobile device.
US Pat. No. 9,399,032

METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS

The General Hospital Corp...

1. A method for reducing organ damage, or the risk of organ damage, resulting from myocardial ischemia, cerebral ischemia,
or renal ischemia, the method comprising administering a therapeutically effective amount of an S-enantiomer of meclizine,
substantially free of the R-enantiomer of meclizine, to a subject in need thereof.

US Pat. No. 9,254,102

METHOD AND APPARATUS FOR IMAGING OF VESSEL SEGMENTS

The General Hospital Corp...

1. An apparatus for imaging a structure, comprising:
an article of manufacture;
a first fluid delivery arrangement configured to deliver a volume of a fluid to an external location with respect to the article
of manufacture; and

an imaging second arrangement configured to obtain information associated with the structure at least one of before, during
or after the volume of the fluid is delivered to the external location, wherein at least one of the second arrangement or
the article of manufacture is translated along a path which approximately corresponds to an axis of extension of a surface,
wherein the translation is automatically performed at a rate of more than 1 mm/second using the information provided from
a processing arrangement,

wherein the first fluid delivery arrangement delivers the fluid to a proximal end of a guide catheter of an article of manufacture,
and wherein the fluid flows through an aperture formed through the guide catheter.

US Pat. No. 10,111,770

METHODS AND DEVICES FOR ACTIVATING BROWN ADIPOSE TISSUE WITH TARGETED SUBSTANCE DELIVERY

Ethicon Endo-Surgery, Inc...

1. A medical device, comprising:a pump configured to be applied to an exterior skin surface of a patient at a depot of brown adipose tissue and in communication with a receptor in communication with at least a portion of the depot of brown adipose tissue,
wherein the pump has an on-board supply of a chemical, and the pump applied to the exterior skin surface delivers the chemical to the patient to activate the brown adipose tissue and increase energy expenditure of the brown adipose tissue, wherein the delivered chemical is configured to chemically interact with cellular surface receptors of the brown adipose tissue, and the chemical comprises one of a depolarization agent, a hormone-related chemical, an odiferous agent, a Melanocortin receptor 4 (MCR4) protein agonist, a TRPA1 agonist, and a TRPV1 agonist.
US Pat. No. 9,855,276

COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

The General Hospital Corp...

1. A method of treating a disease or condition in a human subject in need thereof comprising co-administering about 16 mg/day
or about 20 mg/day of cromolyn or a salt thereof formulated as a dry powder for inhalation, and about 10 mg/day ibuprofen,
wherein the disease or condition is Alzheimer's disease; and the cromolyn and ibuprofen, taken together, are therapeutically
effective.
US Pat. No. 9,549,964

DIAGNOSIS, PROGNOSIS, AND TREATMENT OF KIDNEY DISEASE

Beth Israel Deaconess Med...

1. A method for diagnosing kidney disease, determining the likelihood of developing kidney disease, or determining the severity
of kidney disease in a subject, said method comprising:
(a) determining the fraction of lysine-carbamylated albumin in a biological sample of said subject by:
(i) enzymatically digesting serum proteins in the biological sample; and
(ii) detecting carbamylated albumin that has a carbamylated lysine residue, and
(b) comparing the fraction of lysine-carbamylated albumin in the biological sample of the subject to a control sample,
wherein an increased fraction of lysine-carbamylated albumin in the biological sample of the subject relative to the control
sample is indicative of the presence of kidney disease, an increased likelihood of developing kidney disease, or an increased
kidney disease severity.

US Pat. No. 9,504,394

ELECTRO-OPTICAL SYSTEM, APPARATUS, AND METHOD FOR AMBULATORY MONITORING

The General Hospital Corp...

1. An electro-optical monitoring system comprising:
a light transceiver comprising:
a first light source configured to generate light having a first wavelength, the first light source coupled to receive a first
periodic electrical signal having a first frequency, the first periodic electrical signal amplitude modulating the first light
source to generate first amplitude modulated light, the first light source to transmit the first amplitude modulated light
into biological tissue of a person at a transmission rate of at least 0.1 light transmissions per second;

a second light source configured to generate light having a second different wavelength, the second light source coupled to
receive a second periodic electrical signal having a second different frequency, the second periodic electrical signal amplitude
modulating the second light source to generate second amplitude modulated light, the second light source to transmit the second
amplitude modulated light into the biological tissue of the person at a rate of at least 0.1 light transmissions per second;
and

a light receiver configured to receive light from the biological tissue, the received light indicative of a combination of
the first amplitude modulated light and the second amplitude modulated light having passed into and out of the biological
tissue, the light receiver adapted to provide an electronic transceiver output signal indicative of at least one characteristic
of the received light; and

a processing/storage circuit, comprising:
a first electronic signal source to generate the first periodic electrical signal;
a second electronic signal source to generate the second periodic electrical signal;
an amplitude demodulator configured to amplitude demodulate the transceiver output signal to provide a first demodulated signal
representative of a first characteristic of the received light and to provide a second demodulated signal representative of
a second different characteristic of the received light;

a signal processor coupled to said amplitude demodulator and adapted to process the first demodulated signal and the second
demodulated signal to generate a processed signal, wherein the processed signal includes signal samples having a sample rate
of at least 0.1 samples per second;

and
a storage device coupled to said signal processor and adapted to store at least four hours of the processed signal as a stored-processed
signal, wherein the stored-processed signal has a stored signal duration sufficient to detect an intermittent medical condition
of the person having an occurrence period of at least four hours.

US Pat. No. 10,058,250

SYSTEM, APPARATUS AND METHOD FOR UTILIZING OPTICAL DISPERSION FOR FOURIER-DOMAIN OPTICAL COHERENCE TOMOGRAPHY

The General Hospital Corp...

1. An apparatus, comprising:a laser arrangement which is configured to provide a laser radiation, and including an optical cavity which comprises:
a dispersive optical first arrangement which is configured to receive and disperse at least one first electro-magnetic radiation so as to provide at least one second electro-magnetic radiation,
an active optical modulator second arrangement which is configured to receive and modulate the at least one second radiation so as to provide at least one third electro-magnetic radiation, and
a dispersive optical third arrangement which is configured to receive and disperse at least one third electro-magnetic radiation so as to provide at least one fourth electro-magnetic radiation,
wherein the laser radiation is associated with at least one of the first, second, third or fourth radiations, and wherein at least one of the first arrangement or the third arrangement is a fiber Bragg grating (FBG).

US Pat. No. 9,897,675

MAGNETIC RESONANCE FINGERPRINTING (MRF) WITH SIMULTANEOUS MULTIVOLUME ACQUISITION

Case Western Reserve Univ...

1. A method for creating a parameter map or an image from data acquired by controlling a magnetic resonance imaging (MRI)
apparatus to perform magnetic resonance fingerprinting with simultaneous multivolume acquisition (MRF-SMVA), comprising:
controlling the MRI apparatus to create a first nuclear magnetic resonance (NMR) excitation in a first volume in a sample
according to a first set of magnetic resonance fingerprinting (MRF) parameters;

controlling the MRI apparatus to create a second, different NMR excitation in a second volume in the sample according to a
second set of MRF parameters;

controlling the MRI apparatus to acquire first NMR signals produced by the first volume in response to the first NMR excitation;
producing a first signal evolution from the first NMR signals, the first signal evolution having complex values with an arbitrary
phase relationship;

controlling the MRI apparatus to acquire second NMR signals produced by the second volume in response to the second NMR excitation;
producing a second signal evolution from the second NMR signals, the second signal evolution having complex values with an
arbitrary phase relationship;

simultaneously determining two or more first quantitative magnetic resonance (MR) parameters for a portion of the first volume
based on a comparison of the first signal evolution to one or more known signal evolutions;

simultaneously determining two or more second quantitative MR parameters for a portion of the second volume based on a comparison
of the second signal evolution to one or more known signal evolutions; and

producing the parameter map or the image based, at least in part, on the two or more first quantitative MR parameters or based,
at least in part, on the two or more second quantitative parameters,

where the first NMR excitation and the second NMR excitation are active simultaneously, and
where the first NMR signals and the second NMR signals are acquired simultaneously.

US Pat. No. 9,687,508

METHODS FOR ALLEVIATING ACNE AND METHODS FOR TREATING A SEBACEOUS GLAND

The General Hospital Corp...

1. A method for alleviating acne in a subject comprising:
a) applying a therapeutic substance in a carrier to an area of skin having follicles of a subject in need of acne treatment,
said therapeutic substance comprising a plurality of metal nanoparticles;

b) using a device to impart mechanical energy to deliver some of said therapeutic substance into a plurality of follicles;
c) removing the therapeutic substance remaining on the skin surface while leaving the metal nanoparticles in said follicles;
and

d) irradiating the skin to which the therapeutic substance was applied with infrared light energy effective to treat acne,
thereby alleviating acne in a subject.

US Pat. No. 9,186,067

APPARATUS FOR APPLYING A PLURALITY OF ELECTRO-MAGNETIC RADIATIONS TO A SAMPLE

The General Hospital Corp...

1. An apparatus for applying a plurality of electro-magnetic radiations to a sample, comprising:
an interferometric system;
a catheter arrangement having a specific portion with a plurality of waveguides, and provided in communication with the interferometric
system,

wherein a first one of the waveguides facilitates a first radiation of the radiations to be forwarded to the sample that is
within an anatomical structure, and a second one of the waveguides facilitates a second radiation of the radiations to be
forwarded to the sample, the first radiation having a first wavelength band, and the second radiation having a second wavelength
band, wherein the first wavelength band is different from the second wavelength band,

wherein the interferometric system includes a computer arrangement that is configured to determine information associated
with an effect induced by one of the first radiation or the second radiation on the sample, and

wherein a third one of the waveguides transmits the first and second radiations, and wherein the first and second radiations
transmitted via the third one of the waveguides are separated within the catheter arrangement, and provided into the first
and second ones of the waveguides, respectively; and

a rotary coupler arrangement which receives the radiations via at least one fiber and provides the first radiation to the
waveguides, wherein, when activated, the rotary coupler arrangement causes the specific portion to be continuously rotated
within the anatomical structure.

US Pat. No. 9,132,145

COMPOSITIONS AND METHODS FOR TREATING OBESITY, OBESITY RELATED DISORDERS AND FOR INHIBITING THE INFECTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS

New York University, New...

1. A method for treating a human suffering from obesity comprising administering to said human suffering from obesity a therapeutically
effective amount of a purified oleuropein to treat said obesity in the human.

US Pat. No. 9,940,713

MR-BASED NAVIGATORS FOR INTER-SCAN AND INTRA-SCAN MOTION CORRECTION

Siemens Healthcare GmbH, ...

1. A method for using navigators for inter-scan motion correction during imaging of a subject with a magnetic resonance imaging device, the method comprising:performing an anatomical localizer scan of a region of interest within the subject to identify one or more anatomical landmarks defining orientation of a surrounding field-of-view in the region of interest;
performing an inter-scan motion reference scan of the region of interest to acquire a reference inter-scan dataset indicating a location of a reference navigator in the region of interest;
performing a plurality of scans of the region of interest within the subject to acquire k-space data, wherein, prior to one or more of the plurality of scans, a motion correction process is performed comprising:
performing an inter-scan motion tracking scan to acquire a tracking inter-scan dataset indicating an updated location of the reference navigator in the region of interest,
determining an estimation of inter-scan patient motion based on a comparison between the reference inter-scan dataset and the tracking inter-scan dataset, and
updating the field-of-view relative to the one or more anatomical landmarks in the region of interest based on the estimation of inter-scan patient motion; and
generating one or more images of the region of interest using the k-space data acquired with each of the plurality of scans.
US Pat. No. 9,763,956

DIAGNOSTIC AND TREATMENT METHODS IN SUBJECTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY

The Broad Institute, Inc....

1. A method comprising administering to a subject having cancer a bromodomain inhibitor, with or without a Bcl-2 inhibitor,
and a Notch pathway inhibitor, in an effective amount to treat the cancer, wherein the cancer is characterized by the presence
of a Notch pathway activation mutation.

US Pat. No. 9,211,082

METHOD FOR MAGNETIC RESONANCE IMAGING USING SATURATION HARMONIC INDUCED ROTARY SATURATION

The General Hospital Corp...

1. A method for producing an image of a subject with a magnetic resonance imaging (MRI) system, the steps of the method comprising:
a) administering to the subject, an agent that includes magnetic particles;
b) applying an electromagnetic drive field to the subject at a drive frequency so that the magnetic particles produce magnetic
fields that oscillate at the drive frequency and harmonics thereof;

c) applying a spin-lock pulse to the subject that includes a spin-locking radio frequency (RF) pulse having a spin-lock frequency
that is a harmonic other than a first harmonic of the drive frequency, the spin-lock pulse sequence producing rotary saturation
of nuclear spins affected by the magnetic fields produced by the magnetic particles;

d) acquiring image data from the subject using the MRI system following the application of the spin-lock pulse sequence; and
e) reconstructing an image of the subject from the acquired image data, the reconstructed image depicting an image contrast
indicative of the rotary saturation produced in step c).

US Pat. No. 9,116,153

ARGININE VASOPRESSIN PRO-HORMONE AS PREDICTIVE BIOMARKER FOR DIABETES

B.R.A.H.M.S GMBH, Hennig...

1. A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for identifying
a subject having an enhanced risk for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic
syndrome in a subject wherein said subject is non-diabetic, comprising:
(a) detecting and quantitating the level of a marker consisting of arginine vasopressin pro-hormone or fragments thereof in
a sample from said patient,

wherein said detection and quantitation comprises contacting the sample with a diagnostic assay reagent comprising a capture
probe that specifically binds to arginine vasopressin pro-hormone or a fragment thereof selected from copeptin and neurophysin
II, and detecting and quantitating thus-formed complexes of capture probe and arginine vasopressin pro-hormone, copeptin or
neuorphysin II, and

(b) predicting the risk of the subject for contracting diabetes mellitus and/or metabolic syndrome or inferring from it a
risk for contracting diabetes mellitus and/or metabolic syndrome for said subject or for diagnosing metabolic syndrome in
said subject by comparing the level of arginine vasopressin pro-hormone, copeptin or neurophysin II in the patient to the
level of arginine vasopressin pro-hormone, copeptin or neurophysin II in an ensemble of pre-determined samples in a population
of comparable apparently healthy subjects who later contracted diabetes mellitus or metabolic syndrome or did not contract
said conditions, wherein said prediction or inference is based on a statistically significant correlation of the level of
the marker in the patient sample with the levels of the marker in the pre-determined samples.

US Pat. No. 9,505,735

COMPOUNDS FOR TREATING INFECTIOUS DISEASES

Whitehead Institute for B...

1. A compound of formula I:

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, enantiomer, or diastereomer thereof, wherein:
each one of R1 and R5 is hydrogen;

each one of R3 and R4 is independently selected from the group consisting of hydrogen, halo, —CN, —NO2, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORA, —N(RB)2, —SRA, —C(?O)RA, —C(?O)ORA, —C(?O)SRA, —C(?O)N(RB)2, —OC(?O)RA, —NRBC(?O)RA, —NRBC(?O)N(RB)2, —OC(?O)ORA, —NRBC(?O)ORA, —OC(?O)N(RB)2, —SC(?O)RA, —C(?NRB)RA, —C(?NRB)N(RB)2, —NRBC(?NRB)RB, —C(?S)RA, —C(?S)N(RB)2, —NRBC(?S)RA, —S(?O)RA, —SO2RA, —NRBSO2RA, and —SO2N(RB)2;

each occurrence of RA is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
and each occurrence of RB is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl,
or an amino protecting group, or two RB groups are joined to form an optionally substituted heterocyclic ring;

R2 is —O—Rx;

Rx is optionally substituted C3-8 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, or optionally
substituted heteroaralkyl;

or Rx and R3 are taken together with their intervening atoms to form an optionally substituted heterocyclic ring;

Y is —O— or —S—;
each instance of R11 is independently hydrogen or optionally substituted alkyl;

each instance of R12 is independently hydrogen or optionally substituted alkyl;

L is —C(?O)NR13—;

R13 is hydrogen or C1-6 alkyl;

E is of the formula

s is 1, 2, 3, 4, 5, or 6;
each instance of V1, V2, and V3 is independently N or C, provided that at least one of V1, V2, and V3 is N;

each instance of RE is independently selected from the group consisting of hydrogen, halo, —CN, —NO2, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORA, —N(RB)2, —SRA, —C(?O)RA, —C(?O)ORA, —C(?O)SRA, —C(?O)N(RB)2, —OC(?O)RA, —NRBC(?O)RA, —NRBC(?O)N(RB)2, —OC(?O)ORA, —NRBC(?O)ORA, —OC(?O)N(RB)2, —SC(?O)RA, —C(?NRB)RA, —C(?NRB)N(RB)2, —NRBC(?NRB)RB, —C(?S)RA, —C(?S)N(RB)2, —NRBC(?S)RA, —S(?O)RA, —SO2RA, —NRBSO2RA, and —SO2N(RB)2; and

p is 0, 1, 2, 3, or 4, as valency permits.

US Pat. No. 9,451,979

METHOD AND APPARATUS FOR GRAFTING OF SKIN TISSUE

The General Hospital Corp...

1. An apparatus for forming a plurality of graft tissues, comprising:
a first plate forming a first surface and comprising a plurality of first holes extending from the first surface through the
first plate, wherein the first holes form a pattern of holes distributed across the first surface of the first plate and the
first holes are configured to be aligned to a plurality of raised portions of blisters formed in skin tissue to project through
the first holes;

a second plate forming a second surface and coupled to the first plate, wherein the second plate comprises a plurality of
second holes extending from the second surface through the second plate; and

a cutting arrangement provided between the first surface of the first plate and the second plate, the cutting arrangement
comprising a cutting edge or blade configured to translate across the first surface of the first plate to separate the raised
portions of blisters from the skin tissue at a location where the raised portions of blisters are projecting through the first
holes above the first surface of the first plate.

US Pat. No. 9,242,009

COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES

The General Hospital Corp...

1. A compound comprising a sulfide donor conjugated to an N-methyl-D-aspartate (NMDA) receptor antagonist.
US Pat. No. 9,901,631

METHOD AND CELLS FOR THE PRODUCTION OF VIRAL VACCINES

The Broad Institute, Inc....

1. A virus-infected cell selected from the group consisting of Vero cells, baby hamster kidney (BHK) cells, primary chick
kidney (PCK) cells, Madin-Darby Canine Kidney (MDCK) cells, Madin-Darby Bovine Kidney cells, 293 cells, COS cells and Human
Embryonic Kidney (HEK) 293T cells, which cell produces an increased amount of virus relative to a wild-type cell infected
with the same virus and which cell comprises one or more genes selected from the group consisting of HPS5, HPS1, AP3B1, AP3D,
SC35, APPBP1, CEBPB, NFE2L2, PDGFRL, PPPIRIC, SFRS2, SNAI2, TAF5L, TJP2, TMEM14C, ZNFF331 and ZNF498 whose expression or activity
is reduced or inhibited in said virus-infected cell.

US Pat. No. 9,890,172

INHIBITORS OF HISTONE DEACETYLASE

The Broad Institute, Inc....

1. A method of treating cancer in a subject in need thereof comprising administering to the subject in need thereof an effective
amount of a compound of the formula:
or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein:
the moiety

U is selected from a single bond and NR2d;

V is selected from C and N, provided that when V is N, one of R2a, R2b, or R2c is absent;

each X is independently selected from hydrogen, deuterium, methyl, CF3, and halogen;

R2a is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl;

R2b is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl;

R2c is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl;

R2d is selected from NH2 and C1-C8 alkyl;

provided that:
taken together two of R2a, R2b, and R2c form a C3-C8 cycloalkyl ring, C4-C8 cycloalkenyl ring, or 3 to 8 membered, saturated or partially unsaturated, heterocyclic ring containing 1, 2, 3, or 4 nitrogen
atoms, and the remaining R2a, R2b, or R2c is absent or selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl, wherein:

said cycloalkyl ring formed by taking together two of R2a, R2b, and R2c is substituted with two or more Rx, wherein two Rx are taken together to form a C3-C8 cycloalkyl ring that is substituted with one or more Rz or is unsubstituted, C4-C8 cycloalkenyl ring, or 3 to 8 membered, saturated or partially unsaturated, heterocyclic ring, further wherein said cycloalkenyl
ring and heterocyclic ring are unsubstituted or substituted with one or more Rz, or to form an aromatic ring or heteroaromatic ring, further wherein said aromatic ring and heteroaromatic ring are monocyclic
or bicyclic, and are unsubstituted or substituted with one or more Rz; and

said cycloalkenyl ring formed by taking together two of R2a, R2b, and R2c, and heterocyclic ring formed by taking together two of R2a, R2b, and R2c are unsubstituted or substituted with one or more Rx;

or taken together R2d and one of R2a, R2b, and R2c form a 3 to 8 membered, saturated or partially unsaturated, heterocyclic ring, and: the remaining R2a, R2b, or R2c is selected from hydrogen, halogen, OH, NH2, and C1-C8 alkyl, or taken together two of the remaining R2a, R2b, and R2c form ?O; wherein said heterocyclic ring is unsubstituted or substituted with one or more Rx;

or taken together two of R2a, R2b, and R2c form an aromatic or heteroaromatic ring and the remaining R2a, R2b, or R2c is absent, provided that when two of R2a, R2b, and R2c form an aromatic or heteroaromatic ring and the remaining R2a, R2b, or R2c is absent, U is not a single bond, wherein: said aromatic ring is monocyclic, bicyclic, or tricyclic, and is unsubstituted
or substituted with one or more Rx; and said heteroaromatic ring is monocyclic or bicyclic, and is unsubstituted or substituted with one or more Rx;

each Rx is independently selected from (CH2) zNH2, (CH2)zNHR3, (CH2)zNR3R3, OR3, OCF3, OCH2F, OCHF2, (CH2)z-aromatic ring, (CH2)z-heterocyclic ring, hydroxyl, halogen, C1-C8 alkyl, (C1-C8 alkyl)CF3, (C1-C8 alkyl)OH, C(O)R3, (CH2)zC(O)NH2, (CH2)zC(O)NHR3, (CH2)zC(O)NR3R3, (CH2)zNHC(O)R4, and (CH2)zNR4C(O)R4, wherein the aromatic ring is monocyclic, bicyclic, or tricyclic, and the heterocyclic ring is 3 to 8 membered;

or taken together two Rx attached to the same carbon atom of a cycloalkyl, cycloalkenyl, or heterocyclic ring form ?O;

or taken together two Rx form a C3-C8 cycloalkyl ring, C4-C8 cycloalkenyl ring, or 3 to 8 membered, saturated or partially unsaturated, heterocyclic ring, wherein said cycloalkyl ring,
cycloalkenyl ring, and heterocyclic ring are unsubstituted or substituted with one or more Rz;

or taken together two Rx form an aromatic ring or heteroaromatic ring, wherein: said aromatic ring is monocyclic, bicyclic, or tricyclic, and is unsubstituted
or substituted with one or more Rz; and said heteroaromatic ring is monocyclic or bicyclic, and is unsubstituted or substituted with one or more Rz;

each Rz is independently selected from halogen, C1-C4 alkyl, OH, OR3, CF3, OCF3, OCH2F, OCHF2, NH2, NHR3, NR3R3, and C(O)CH3;

R3 is C1-C8 alkyl;

R4 is selected from C1-C8 alkyl and CF3;

R5 is selected from hydrogen, deuterium, halogen, OH, OCH3, CF3, CH3, and cyclopropyl;

t is 0, and
z is selected from 0, 1, 2, and 3.

US Pat. No. 9,299,156

STRUCTURE-ANALYSIS SYSTEM, METHOD, SOFTWARE ARRANGEMENT AND COMPUTER-ACCESSIBLE MEDIUM FOR DIGITAL CLEANSING OF COMPUTED TOMOGRAPHY COLONOGRAPHY IMAGES

The General Hospital Corp...

1. A structure-analysis method configured for providing imaging information with respect to a patient obtained during a virtual
colonoscopy, comprising:
a) generating as part of, or following a virtual colonoscopy, at least one colonography image of at least one region of interest
of the patient, the at least one generated colonography image comprising tagged bowel contents of at least one portion of
a colon of the patient; and

b) classifying one or more morphological features in the at least one generated colonography image as at least one of a polyp
or a fold;

c) while at least subtracting or removing, either digitally or electronically, the tagged bowel contents from the at least
one generated colonography image, based on the morphological classification, either during or following the classifying step,
in order to provide the imaging information, with respect to the patient, as a reconstructed, displayed, and/or stored image.

US Pat. No. 9,132,143

USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEASE

The General Hospital Corp...

1. A method for treating or reducing a risk of sepsis and necrotizing enterocolitis (NEC), the method comprising:
administering to an individual in need thereof an effective amount of a composition comprising one or more alpha-1,2 fucosyl
glycans,

wherein the individual has a level of at least one antigen that differs from a predetermined value or is outside a predetermined
range of values, the at least one antigen being selected from the group consisting of H-1, H-2, Lewisb, Lewisy, sulfated or sialylated H-1, sulfated or sialylated H-2, sialylated Lewisa, sulfated or sialylated Lewisb, and sulfated or sialylated Lewisy,

and wherein the one or more alpha-1,2 fucosyl glycans are purified, synthesized chemically, or synthesized enzymatically using
engineered microorganisms.

US Pat. No. 10,024,860

CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS

Massachusetts Institute o...

1. A method of delivering an active agent to a tumor, comprising administering to a subject having a tumor that is a mammary carcinoma, a binding reagent which interacts specifically with an extracellular matrix (ECM) protein, wherein the binding reagent is conjugated to an active agent in an effective amount to deliver the active agent to the tumor, wherein the ECM protein is characteristic of mammary carcinoma and is selected from a signature of ECM proteins, referred to as Group A, comprising COL17A1, COL19A1, Col28a1, COL6A6, EMID2, FLG2, Gm7455, Hmcn1, HRNR, Itih3, NGLY1, PRELP, Vwa1, AGRN, C1qc, COL22A1, COL23A1, COL24A1, EFEMP2, F10, F13b, HCFC2, HTRA1, Itih4, LEPREL2, LTBP3, MFGE8, P4HTM, Pap1n, Plxnb2, Serpina1b, Serpinf1, SNED1, SRPX, and TINAGL1.

US Pat. No. 9,919,059

MULTISTAGE NANOPARTICLE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF SOLID TUMORS

Massachusetts Institute o...

1. A polymer-drug conjugate defined by Formula I or Formula IV
or
wherein
A is, independently for each occurrence, a therapeutic, prophylactic or diagnostic agent;
S is absent, or is a spacer group;
X is a hydrophilic polymer segment comprising a graft copolymer, wherein the graft copolymer comprises a polymeric backbone
comprising a poly(amino acid), wherein the backbone is functionalized by one or more hydrophilic polymeric side chains;

L is absent, or is a hydrolysable or enzymatically cleavable linking group;
Y is a hydrophobic polymer segment;
b and c are independently integers between 1 and 100,
A? is, independently for each occurrence, anti-neoplastic drug;
X? is a hydrophilic polymer segment comprising a graft copolymer, wherein the graft copolymer comprises a polymeric backbone
comprising a poly(amino acid), wherein the backbone is functionalized by one or more hydrophilic polymeric side chains, wherein
the graft copolymer has a grafting ratio of between about 1.5% and 60%;

Y? is a poly(alkylene oxide) or copolymer thereof; and
wherein the conjugates are capable of forming nanoparticles having a diameter between about 80 nm and about 500 nm, having
hydrophilic polymer on the outer surface and a hydrophobic polymer core, and wherein the nanoparticles release smaller nanoparticles
upon exposure to hydrolysis or an enzyme in a tumor microenvironment.

US Pat. No. 9,808,803

SYSTEMS AND METHODS FOR PARTICLE FOCUSING IN MICROCHANNELS

The General Hospital Corp...

1. A system for focusing and ordering particles suspended within a moving fluid into one or more localized stream lines, comprising:
a substrate;
at least one expanding spiral-shaped channel having a rectangular cross-section provided on the substrate, wherein the at
least one expanding spiral-shaped channel comprises an inlet at or near an inner end of the expanding spiral-shaped channel
and at least two outlets at or near an outer end of the expanding spiral-shaped channel, and wherein a radius of curvature
of the spiral-shaped channel increases from the inner end to the outer end; and

a pumping element configured to move the fluid and particles along the at least one expanding spiral-shaped channel in one
direction and in a laminar flow;

wherein the fluid, the channel, and the pumping element are configured to cause inertial forces to act on the particles to
focus the particles into one or more stream lines and to order the particles with a uniform spacing in the direction of the
flow.

US Pat. No. 9,402,852

METHOD TO ENHANCE TISSUE REGENERATION

The General Hospital Corp...

1. An ex vivo or in vivo method for promoting the growth or regeneration, of non-cancerous tissue comprising
contacting said tissue with a prostaglandin signaling pathway activator and a wnt pathway activator thereby promoting tissue
growth or regeneration,

wherein the prostaglandin signaling pathway activator is selected from the group consisting of: prostaglandin E2 (PGE2), prostaglandin
12 (PG12), 16-phenyl tetranor PGE2, 16,16-dimethyl PGE2, 19(R)-hydroxy PGE2, 16,16-dimethyl PGE2 p-(p-acetamidobenzamido)phenyl
ester, 0-deoxy-9methylene-16,16-dimethyl PGE2, PGE2 methyl ester, Butraprost, 15(S)-15-methyl PGE2, 15(R)-15-methyl PGE2,
20-hydroxy PGE2,11-deoxy-16,16-dimethyl PGE2,9-deoxy-9-methylene PGE2, PGE2 serinol amide, and Sulprostone, and

wherein the wnt pathway activator is selected from the group consisting of 6-bromoindirubin-3-oxime (BIO), LiCl, and soluble
Wnt ligand.

US Pat. No. 9,393,221

METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE

THE GENERAL HOSPITAL CORP...

1. A method for reducing intracellular lipid accumulation in a cell comprising contacting the cell in vitro or in vivo with
an effective amount of a compound selected from Table 3, wherein the effective amount of the compound shifts cellular energy
metabolism from fatty acid oxidation to glycolysis, thereby reducing intracellular lipid accumulation within the cell, wherein
the cell has reduced Adipose Triglyceride Lipase (ATGL) function due to a loss of function mutation in the gene PNPLA2.
US Pat. No. 9,132,142

USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEASE

The General Hospital Corp...

1. A method for treating necrotizing enterocolitis (NEC), the method comprising:
administering to an infant having NEC an effective amount of a composition comprising one or more alpha-1,2 fucosyl glycans,
wherein the infant is a premature infant or an infant having a birth weight of less than 2500 grams, and
wherein the one or more alpha-1,2 fucosyl glycans are either purified from a natural source or chemically synthesized.
US Pat. No. 9,229,004

METHODS FOR DETECTING AND TREATING CANCER

THE GENERAL HOSPITAL CORP...

1. A method for staging cervical neoplasia in a subject and administering a treatment correlated to a good clinical outcome
for the stage of cervical neoplasia, the method comprising:
A) performing an assay to measure the level of a CXCL 12 polypeptide having a molecular weight greater than about 10 kD or
11 kD in the cervical neoplasia;

B) comparing the level of the CXCL 12 polypeptide in the cervical neoplasia to a reference level;
C) classifying the stage of the cervical neoplasia in the subject as a pre-invasive stage or an invasive stage of cervical
neoplasia based on the comparison to the reference level wherein an increase in the level of the CXCL12 polypeptide relative
to the reference level indicates an invasive stage and a lack of an increase in the level of the CXCL12 polypeptide relative
to the reference level indicates a pre-invasive stage; and

D) administering a less aggressive treatment to the subject having a pre-invasive stage of cervical neoplasia, or a more aggressive
treatment to the subject having an invasive stage of cervical neoplasia
thereby staging cervical neoplasia in the subject and administering a treatment correlated to a good clinical outcome for
the stage of cervical neoplasia.
US Pat. No. 9,155,723

ANTI-CXCR4 AS A SENSITIZER TO CANCER THERAPEUTICS

THE GENERAL HOSPITAL CORP...

1. A method of treating a cancer tumor in a subject in need thereof, comprising:
administering an anti-tumor therapy to the subject; and
administering a therapeutically effective amount of a CXCR4 inhibitor to the subject within 5 days of administering the anti-tumor
therapy;

measuring the level of CXCL12 expression in the subject;
comparing the level of CXCL12 expression in the subject to a reference level;
and administering the CXCR4 inhibitor to the subject until CXCL12 expression is within 10% of the reference level.

US Pat. No. 9,060,865

MONOPOLAR CONSTRAINED ACETABULAR COMPONENT

The General Hospital Corp...

1. A metallic constraining ring that fastens directly to a cut-away monopolar constrained acetabular liner, wherein the constraining
ring has at least one positioned recess that is compatible with at least one recess on the cut-away monopolar constrained
acetabular liner that comprises cross-linked ultrahigh molecular weight polyethylene, wherein the metallic constraining ring
fits around the perimeter of the cut-away monopolar constrained acetabular liner, and wherein the metallic constraining ring
is set onto the cut-away monopolar constrained acetabular liner during the operative procedure after the femoral head is reduced
into the cut-away monopolar constrained acetabular liner, wherein following the operative procedure the metallic constraining
ring is not impinged by a femoral neck, wherein at least one recess can be positioned to increase range of motion.
US Pat. No. 9,610,429

METHODS AND DEVICES FOR ACTIVATING BROWN ADIPOSE TISSUE WITH TARGETED SUBSTANCE DELIVERY

Ethicon Endo-Surgery, Inc...

1. A medical method, comprising:
transcutaneously applying a device in contact with an exterior skin surface of a patient at a depot of brown adipose tissue
and in communication with a receptor in communication with at least a portion of the depot of brown adipose tissue, wherein
the device is one of a patch and a pump; and

activating the device to deliver a chemical from the device to the patient to activate the brown adipose tissue and increase
energy expenditure of the brown adipose tissue, wherein the delivered chemical chemically interacts with cellular surface
receptors of the brown adipose tissue, and the chemical comprises one of a depolarization agent, a hormone-related chemical,
an odiferous agent, a Melanocortin receptor 4 (MCR4) protein agonist, a TRPA1 agonist, and a TRPV1 agonist.

US Pat. No. 9,606,131

ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY

The General Hospital Corp...

1. A method comprising:
determining a level of bioavailable Vitamin D in a subject by directly detecting levels of free Vitamin D and Vitamin D bound
to albumin in a sample comprising serum or plasma from the subject using a differential affinity precipitation assay; and

detecting the presence of a vitamin D binding protein variant genotype in the subject.
US Pat. No. 9,526,800

CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS

Massachusetts Institute o...

1. A method of delivering an active agent to a tumor for treating or developing treatments, comprising
administering to a colon cancer subject having a tumor binding reagents each of which interact specifically with an extracellular
matrix (ECM) protein of a set of proteins characteristic of an ECM protein signature, wherein the binding reagents are conjugated
to active agents in an effective amount to deliver the active agents to the tumor, wherein the signature ECM proteins includes
at least 3 of the proteins selected from an ECM protein signature defined as being characteristic of metastatic primary colon
carcinoma (group 4) but not including MMP9, MMP2, SPARC and/or TGF?1, colon carcinoma metastases (group 5) but not including
SPP1, metastatic colon carcinoma (primary & secondary) (group 6) but not including CTSB and/or S100A8, or a signature whose
expression is associated with colon cancer or metastatic colon cancer (group 7) but not including MMP9, MMP2, SPARC, TGF?1,
SPPI, LOXL2, CTSB and/or S100A8.

US Pat. No. 9,523,752

INTERFACE FOR MEDICAL IMAGING DEVICE

The General Hospital Corp...

1. A magnetic resonance imaging (MRI) system comprising:
a magnet system configured to generate a polarizing magnetic field about at least a portion of a subject;
a plurality of gradient coils configured to apply a gradient field to the polarizing magnetic field;
a radio frequency (RF) system configured to apply an excitation field to the subject and acquire MR image data therefrom;
a wireless electronic device configured to be used proximate to the magnet system and including a tilt sensor, the wireless
electronic device being configured to monitor a tilt of the wireless electronic device; and

a computer system programmed to:
receive an indication of the tilt of the wireless electronic device,
receive, via a user interface of the wireless electronic device, a selection of one of a plurality of translation scales,
each one of the plurality of translation scales for translating the indication of the tilt of the wireless electronic device
into different movements of an imaging plane of the MRI system,

determine, using the indication of the tilt of the wireless electronic device and the selection of the one of the translation
scales, a corresponding movement operation of the plurality of gradient coils and RF system to move the imaging plane of the
MRI system, and

operate at least one of the plurality of gradient coils and RF system to cause the corresponding movement of the imaging plane.

US Pat. No. 9,506,846

HIGH DEFINITION NANOMATERIALS

Massachusetts Institute o...

1. A fluidic device for manipulating particles comprising:
a substrate that defines a fluid path; and
one or more obstacles, each obstacle comprising a plurality of aligned nanostructures, wherein the nanostructures are coated
with one or more layers of a plurality of nanoparticles and a plurality of polymer layers, wherein nanostructures form an
outer surface of an obstacle in the fluid path; wherein the one or more obstacles are fixedly arranged within the fluid path
such that some expected paths within the fluid path pass around the outer surface of an obstacle and some expected paths within
the fluid path pass through the outer surface of an obstacle and into a network of spaces within the obstacle between the
nanostructures.

US Pat. No. 9,387,152

BLOOD SUBSTITUTES AND USES THEREOF

THE GENERAL HOSPITAL CORP...

1. A method of encapsulating a blood substitute composition, the method comprising the steps of:
a. mixing a lipid preparation with a composition comprising an oxido-reductase enzyme, a dismutase, a catalase, a reducing
agent, and an electron acceptor;

b. extruding the mixture to form lipid vesicles; and
c. isolating lipid vesicles, wherein the lipid preparation comprises at least one lipid selected from the group consisting
of: DPPC, DSPC, DOPC, DLPC, DPPG, DSPG, DHPG, DOPG, DSPEG PEG 5000, DSPE-PEG200, and DOPE-PEG5000,

and, wherein electron acceptors include but are not limited to: methylene blue, sodium 2,6-dibromophenol-indophenol, sodium
2,6-dichlorophenol-indophenol, sodium o-cresol indophenols, indigotetrasulfonic acid, indigotrisulfonic acid, indigo carmine,
indigomono sulfonic acid, phenosafranin, safranin T, neutral red, and thionine.

US Pat. No. 9,377,290

METHOD AND APPARATUS FOR PERFORMING OPTICAL IMAGING USING FREQUENCY-DOMAIN INTERFEROMETRY

The General Hospital Corp...

1. An apparatus, comprising:
at least one first arrangement including a light source that is configured to provide a radiation which includes at least
one first electro-magnetic radiation directed to a sample and at least one second electro-magnetic radiation directed to a
reference, wherein the light source causes a frequency of the radiation provided by the at least one first arrangement to
vary over time;

at least one second arrangement including a detector that is configured to detect an interference between at least one third
radiation associated with the at least one first radiation and at least one fourth radiation associated with the at least
one second radiation to generate an electrical first signal, wherein the at least one second arrangement is configured to
obtain a second signal associated with at least one phase of at least one frequency component of the electrical first signal;
and

a computer which generates comparison data by comparing the second signal to at least one particular information.

US Pat. No. 9,295,391

SPECTRALLY ENCODED MINIATURE ENDOSCOPIC IMAGING PROBE

The General Hospital Corp...

1. An apparatus for obtaining information associated with an anatomical structure, comprising:
a housing;
at least one lens that is different from the housing, and which is configured to provide there through electro-magnetic radiation,
wherein the electro-magnetic radiation is provided by at least one of a broadband source or a wavelength tuned source;

an optical waveguide configured to transmit the electro-magnetic radiation from the structure;
at least one further arrangement including a computer which is structured to obtain the information based on the electro-magnetic
radiation obtained from the structure, wherein the information is at least one of a two-dimensional image or a three dimensional
image; and

a dispersive arrangement including a grating which is configured to receive at least one portion of the electro-magnetic radiation
and forward a dispersed radiation thereof to at least one section of the structure regarding which the information is being
obtained, wherein the grating has a groove density that is at least 1200 lines/mm, wherein the lens and the dispersive arrangement
are provided within at least one portion of the housing and in an optical path between the optical waveguide and a location
of the apparatus at which the electro-magnetic radiation is received from the anatomical structure, and wherein the at least
one portion of the housing has a diameter of at most 1 mm.

US Pat. No. 9,261,496

DEVICE FOR HIGH THROUGHPUT INVESTIGATIONS OF MULTI-CELLULAR INTERACTIONS

Massachusetts Institute o...

1. A microfluidic device comprising:
a substrate comprised of an optically transparent material and further comprising
i) one or more fluid channels;
ii) one or more fluid channel inlets;
iii) one or more fluid channel outlets;
iv) one or more gel cage regions; and
v) a plurality of posts;wherein
all or a portion of each gel cage region is flanked by all or a portion of one or more fluid channels, thereby creating one
or more gel cage region-fluid channel interface regions; and

each gel cage region comprises at least one row of posts which forms the gel cage region, each post of the at least one row
of posts forming a triangular shape, a trapezoidal shape or a combination thereof, the sum of a contact angle of a gel on
a surface of the substrate and an internal angle of a corner of each post of the at least one row of posts being about 180°,
and a distance between each neighboring pair of posts in the at least one row of posts being from about 50 micrometers to
about 300 micrometers.

US Pat. No. 9,057,727

SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS

The General Hospital Corp...

1. A method for identifying a candidate compound as a long-acting agonist of a secretin family receptor, said method comprising:
(a) contacting said secretin family receptor with said compound, wherein said secretin family receptor is in the RG form;
(b) measuring the affinity of said compound for the RG form of said secretin family receptor;
(c) contacting said secretin family receptor with said compound, wherein said secretin family receptor is in the R0 form;

(d) measuring the affinity of said compound for the R0 form of said secretin family receptor; and

(e) identifying said compound as a long-acting agonist of said secretin family receptor if said compound
(i) has an affinity for the RG form of said secretin family receptor that is at least 10% of the affinity of an endogenous
agonist for the RG form of said secretin family receptor, and

(ii) has a greater affinity for the R0 form of said secretin family receptor than the affinity of said endogenous agonist for the R0 form of said secretin family receptor.

US Pat. No. 10,059,941

COMPOSITIONS AND METHODS FOR MODULATING SMN GENE FAMILY EXPRESSION

Translate Bio MA, Inc., ...

1. A composition comprising a cell and a single stranded oligonucleotide, wherein the single stranded oligonucleotide is produced by a process comprising:synthesizing a single stranded oligonucleotide that:
(a) has a sequence 5?-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 8 nucleotides in length,
(b) is 100% complementary with a PRC2-associated region of an SMN gene, wherein the PRC2-associated region is a region of the SMN gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the SMN gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody, and
(c) is 8 to 15 nucleotides in length,
wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue and/or a modified internucleotide linkage is incorporated between at least two nucleotides.

US Pat. No. 9,964,616

FAST GROUP MATCHING FOR MAGNETIC RESONANCE FINGERPRINTING RECONSTRUCTION

Case Western Reserve Univ...

1. A non-transitory computer-readable storage medium storing computer executable instructions that when executed by a computer control the computer to perform a method for producing a quantitative parameter map, comprising:accessing a comprehensive dictionary of predicted magnetic resonance fingerprinting (MRF) signal evolutions, where a signal evolution includes complex values with an arbitrary phase relationship;
generating a grouped dictionary based on the comprehensive dictionary, where the grouped dictionary includes a plurality of groups, where a group includes a plurality of correlated signal evolutions, a group representative signal that represents the group, and a group low-rank representative;
accessing patient data, where the patient data includes a patient MRF signal evolution, where the patient MRF signal evolution includes complex values with an arbitrary phase relationship;
comparing the patient MRF signal evolution with the group representative signal from a threshold number of the plurality of groups;
upon determining that the group representative signal from the threshold number does not match the patient MRF signal evolution to within a desired threshold,
generating a pruned dictionary by removing from consideration, from the grouped dictionary, the groups represented by the threshold number of representative signals that do not match the patient MRF signal evolution;
selecting a matched signal evolution by matching, to within a threshold quality of fit, the patient MRF signal evolution with a signal evolution in the pruned dictionary, where the matching is based on the group low-rank representative, where the threshold quality of fit is a dynamic, adaptive threshold;
determining a quantitative parameter for the patient MRF signal evolution based on the matched signal evolution; and
generating a patient image based, at least part, on the quantitative parameter.

US Pat. No. 9,812,846

METHOD AND APPARATUS FOR PERFORMING OPTICAL IMAGING USING FREQUENCY-DOMAIN INTERFEROMETRY

THE GENERAL HOSPITAL CORP...

1. An apparatus comprising:
a light source arrangement configured to emit an electromagnetic radiation, wherein the light source arrangement includes
a cavity and a filter which cause a spectrum of the electromagnetic radiation to have a mean frequency that changes (i) at
an absolute rate that is greater than about 100 terahertz per millisecond, and (ii) over a range that is greater than about
10 terahertz.

US Pat. No. 9,688,004

METHODS FOR MAKING OXIDATION RESISTANT POLYMERIC MATERIAL

The General Hospital Corp...

1. A method of making a medical implant comprising antioxidant-blended non-oxidizing polymeric material containing detectable
residual free radicals, wherein the method comprising the steps of:
(i) blending polymeric material with an antioxidant in the absence of a supercritical fluid, thereby forming an antioxidant-blended
polymeric material;

(ii) consolidating the antioxidant-blended polymeric blend;
(iii) irradiating the consolidated polymeric blend material with ionizing radiation at an elevated temperature that is above
room temperature and below the melting point of the polymeric material, thereby forming the antioxidant-blended cross-linked,
and non-oxidizing polymeric material containing detectable residual free radicals, wherein the consolidated polymeric blend
material is irradiated with a dose ranging from about 25 kGy to about 1000 kGy; and

(iv) machining the consolidated cross-linked polymeric blend material, thereby forming the medical implant.
US Pat. No. 9,289,492

COLLECTING OVARIAN CANCER STEM CELLS FROM OVARIAN CANCER CELLS

The General Hospital Corp...

1. A method for collecting a population of ovarian cancer stem cells, the method comprising
(i) contacting a biopsy tissue sample comprising a population of ovarian cancer cells with an anti-EpCam, an anti-cytokeratin-8
and an anti-?-catenin antibody, antibody derivative or fragment thereof;

(ii) separating the ovarian cancer cells that are positive for binding the combination of anti-EpCam, anti-cytokeratin-8,
and anti-?-catenin antibodies, from the ovarian cancer cells that do not bind all three of the antibodies;

(iii) collecting the ovarian cancer cells that are positive for the binding of the combination of anti-EpCam, anti-cytokeratin-8,
and anti-?-catenin antibodies, wherein the isolated ovarian cancer cells comprises ovarian cancer stem cells.

US Pat. No. 9,291,616

FUNGAL-DERIVED CARBOHYDRATE-CONJUGATED SCAFFOLD

THE GENERAL HOSPITAL CORP...

1. An assay for determining whether a population of cells is immunocompromised for fungal infection comprising:
obtaining a population of cells;
contacting the cells with an artificial fungus-like particle comprising a purified fungal cell wall carbohydrate conjugated
to a polymer bead;

observing the response of the cells to the particle; and
comparing the response with a known response of a healthy, immunocompetent cell population.

US Pat. No. 9,156,825

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

THE GENERAL HOSPITAL CORP...

1. A compound according to formula (I)

wherein,
R1 is L1C(O)OL2-[C(R7R8)]p—C(R9R10)—C(O)OT;

R2 is R1, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, or optionally substituted linear or branched C2-C10 alkynyl, wherein the backbone of C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl optionally comprises one or more heteroatoms;

each R3 is independently halogen, CN, CF3, SR2, SOR2, SO2R2, OR2, CO2H, CO2R2, N(R2)2, NHR2, NO2, or R2;

Z is N or CR6;

R4, R5, and R6 are independently hydrogen, halogen, CN, CF3, SR2, SOR2, SO2R2, OR2, CO2H, CO2R2, N(R2)2, NHR2, NO2, or R2;

R7 and R8 are independently hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, or R7 and R8 together with the carbon they are attached to form an optionally substituted 3-8 membered cyclyl or heterocyclyl;

R9 and R10 are independently hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted C4-C8 cyclyl, optionally substituted C3-C8 heterocyclyl, or R9 and R10 together with the carbon they are attached to form an optionally substituted 3-8 membered cyclyl or heterocyclyl, or

R7 and R9 together with the carbons they are attached to form an optionally substituted 3-8 membered cyclyl, heterocyclyl, aryl or heteroaryl;

L1 and L2 are independently a bond, optionally substituted linear or branched C1-C10 alkylene, optionally substituted linear or branched C2-C10 alkenylene, or optionally substituted linear or branched C2-C10 alkynylene, wherein the backbone of C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene optionally comprises one or more heteroatoms;

T is H, a linear or branched, substituted or unsubstituted C1-C10 alkyl, linear or branched, substituted or unsubstituted C2-C10 alkenyl, linear or branched, substituted or unsubstituted C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocylcyl, optionally substituted aryl, optionally substituted
heteroaryl, or PEG, wherein the backbone of C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl optionally comprises one or more heteroatoms;

n is an integer from 0-5; and
p is 0 or 1, provided that at least one of R7, R8, R9 and R10 is not hydrogen,

or a salt, solvate, or ester thereof.

US Pat. No. 9,097,644

MAGNETIC RESONANCE-BASED VISCOMETERS AND METHODS

Massachusetts Institute o...

1. A method for determining viscosity of a liquid, wherein the liquid comprises a solvent, the method comprising:
(i) exposing a sample comprising the liquid and two or more non-settling particles, each of the particles having a positive
magnetic susceptibility and a magnetic moment of at least about 6 ×10?16 emu per particle, to an applied magnetic field, wherein the applied magnetic field is of a strength sufficient to induce the
particles to aggregate; and

(ii) measuring a change in a nuclear relaxation property of the solvent caused by aggregation of the particles in the applied
magnetic field;

wherein a change in the nuclear relaxation property relates to the viscosity of the liquid.
US Pat. No. 9,072,740

METHODS OF IMPROVING CENTRAL NERVOUS SYSTEM FUNCTIONING

The General Hospital Corp...

1. A method for treating a human patient suffering from stroke, said method comprising administering to said patient a therapeutic
dose of cells isolated from human umbilical cord blood (UCB), wherein said cells comprise human CD34+, Lin? cells separated
from other mononuclear cells present in said UCB prior to said administering,
wherein said administering results in a measurable improvement in said stroke in said patient, and wherein said cells are
administered to said patient intravenously, intracerebrally, intracisternally, intracerebroventricularly, or intraparenchymally.

US Pat. No. 9,045,484

INHIBITORS OF THE BMP SIGNALING PATHWAY

The General Hospital Corp...

1. A method of inhibiting BMP-induced phosphorylation of SMAD1/5/8, comprising contacting the cell with a compound having
a structure of Formula I:
wherein:
X and Y are each N;
Z is CR3;

Ar is selected from substituted or unsubstituted aryl and heteroaryl;
L1 is absent or selected from substituted or unsubstituted alkyl and heteroalkyl;

A and B are both CR16;

E and F are both CR5 and both occurrences of R5 taken together with E and F form a substituted or unsubstituted 5- or 6-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
ring;

R3 is selected from H and substituted or unsubstituted alkyl;

R4 is selected from H and substituted or unsubstituted alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carboxyl,
ester, hydroxyl, alkoxyl, alkylthio, acyloxy, amino, acylamino, carbamate, amido, amidino, sulfonyl, sulfoxido, sulfamoyl,
or sulfonamido;

R15 independently for each occurrence, is selected from H and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl,
heterocyclylalkyl, halogen, acylamino, carbamate, cyano, sulfonyl, sulfoxido, sulfamoyl, or sulfonamido;

R16, independently for each occurrence, is absent or is selected from H and substituted or unsubstituted alkyl, alkenyl, alkynyl,
aralkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, cycloalkylalkyl, heterocyclylalkyl, halogen, acyl, carboxyl,
ester, hydroxyl, alkoxyl, alkylthio, acyloxy, amino, acylamino, carbamate, amido, amidino, cyano, sulfonyl, sulfoxido, sulfamoyl,
or sulfonamido,
or a pharmaceutically acceptable salt thereof.
US Pat. No. 9,952,229

ARGININE VASOPRESSIN PRO-HORMONE AS PREDICTIVE BIOMARKER FOR DIABETES

B.R.A.H.M.S. GmbH, Henni...

1. A method for diagnosing metabolic syndrome in a subject comprising:a. detecting and quantitating the level of arginine vasopressin pro-hormone copeptin fragment in a sample from said patient,
wherein said detection and quantitation comprises contacting the sample with a diagnostic assay reagent comprising at least one monoclonal antibody or fragment thereof that specifically binds to the arginine vasopressin pro-hormone copeptin fragment at the epitope corresponding to amino acids 132-147 of pre-pro-vasopressin of SEQ ID NO: 1, and detecting and quantitating thus-formed complexes of the antibody or fragment thereof and arginine vasopressin pro-hormone copeptin fragment,
b. detecting and quantitating at least one other clinical and/or laboratory parameter associated with the diagnosis of metabolic syndrome, and
c. correlating the level of the arginine vasopressin pro-hormone copeptin fragment in conjunction with the at least one other clinical and/or laboratory parameter associated with the diagnosis of metabolic syndrome, with the diagnosis of metabolic syndrome.

US Pat. No. 9,944,668

MANGANESE-BASED MAGNETIC RESONANCE CONTRAST AGENTS

The General Hospital Corp...

1. A contrast agent for magnetic resonance imaging, the contrast agent comprising a compound of Formula (IX):
US Pat. No. 9,267,111

METHODS OF TREATING FEMALE SUBJECTS IN NEED OF IN VITRO FERTILIZATION

The General Hospital Corp...

1. A method of providing in vitro fertilization to a female subject in need thereof, said method comprising the steps of:
a) determining the presence or absence of Vasa expression in a sample of peripheral blood obtained from the female subject,
wherein the absence of Vasa expression corresponds to a loss of non-atretic follicles in the female subject compared to a
female subject having a functional reproductive system; and

b) providing in vitro fertilization to the female subject.

US Pat. No. 9,226,645

SYSTEM AND METHOD FOR NORMALIZED DIFFUSE EMISSION EPI-ILLUMINATION IMAGING AND NORMALIZED DIFFUSE EMISSION TRANSILLUMINATION IMAGING

The General Hospital Corp...

1. A method of imaging, comprising:
generating incident light including excitation light with an excitation light source, wherein the excitation light source
comprises an epi-illumination light source;

directing the incident light toward a tissue;
receiving the incident light with a light detector after the incident light has interacted with a tissue;
receiving emitted light with the light detector, wherein the emitted light is emitted from the tissue;
generating an excitation image of the tissue in response to received incident light, wherein the excitation image is obtained
at a wavelength of the excitation light, wherein the excitation light is near-infrared light;

generating an un-normalized emitted light image of the tissue in response to the received emitted light, wherein the un-normalized
emitted light image comprises an un-normalized fluorescence epi-illumination image generated at a selected wavelength different
than the wavelength of the excitation light; and

dividing the un-normalized emitted light image by the excitation image to generate a normalized emitted light image of the
tissue.

US Pat. No. 10,611,738

FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS

The General Hospital Corp...

1. A peptide, polypeptide or protein comprising incorporated therein a tetrazine-substituted amino acid unit derived from an amino acid of the following formula (I)
wherein:
R1 is hydrogen, (C1-C6)alkyl or substituted (C1-C6)alkyl;
A or is a group selected from groups of formulae (A2), (A3), (A4) and (A5):

n1 is 1, 2, 3, 4, 5, or 6;
n2 is 0, 1, 2, 3, 4, 5 or 6; and
a and b denote bonds attaching A to the remainder of the amino acid unit.
US Pat. No. 9,527,906

IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES

The General Hospital Corp...

1. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a heat shock protein fused to a biotin-binding
protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated engineered antibody, the biotinylated
engineered antibody is a biotin-containing recombinant molecule that comprises at least an antibody fragment, and the antibody
fragment comprises an antigen binding site.

US Pat. No. 9,469,606

WNT/B-CATENIN INHIBITORS AND METHODS OF USE

The General Hospital Corp...

1. A method of treating cancer in a patient, the method comprising administering to the patient a therapeutically effective
amount of a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 9,417,298

LOCAL SAR REDUCTION IN MULTI-SLICE PTX VIA SAR-HOPPING BETWEEN EXCITATIONS

The General Hospital Corp...

1. A method for designing parallel transmission (pTx) radio frequency (RF) pulses for use in multislice magnetic resonance
imaging (MRI), the steps of the method comprising:
a) determining a target magnetization to be achieved in a plurality of slice locations in a subject;
b) selecting a set of compressed specific absorption rate (SAR) matrix points at which SAR can be evaluated;
c) designing a plurality of RF pulses for achieving the target magnetization by determining a set of RF waveforms that minimize
an average local SAR of the plurality of RF pulses evaluated at the compressed SAR matrix points; and d) making the plurality
of RF pulses designed in step c) accessible to an MRI system to perform multislice MRI.

US Pat. No. 9,332,942

SYSTEMS, PROCESSES AND COMPUTER-ACCESSIBLE MEDIUM FOR PROVIDING HYBRID FLOURESCENCE AND OPTICAL COHERENCE TOMOGRAPHY IMAGING

THE GENERAL HOSPITAL CORP...

1. An apparatus for obtaining information regarding at least one portion of a chosen biological target, comprising:
a catheter having proximal and distal ends and an axis and including a first channel and a second channel,
wherein the first and second channels together are configured to transmit at least first, second, and third radiations,
wherein said first channel includes a first optical waveguide and is configured to transmit through the distal ends towards
the proximal end, the first radiation that includes one of a mechanical radiation and an optical radiation including fluorescent
radiation, the first radiation generated within said biological target in response to absorption by said target of third radiation
transmitted through catheter from the proximal end;

wherein said second channel includes a second optical waveguide and is configured to transmit, from said biological target
through the distal end towards the proximal end, the second radiation representing anatomical characteristics of said target
and containing optical-computed-tomography (OCT) information;

wherein each of the first and second channels is structured to deflect a radiation transmitted through such channel to cause
said radiation to traverse a first portion of such channel along the axis and a second portion of such channel along a line
that is transverse to the axis;

wherein said first optical waveguide dimensioned to channel only the first radiation and the second optical waveguide is dimensioned
to channel only the second radiation;

wherein the catheter is configured to outcouple said first and second radiations from the first and second optical waveguides
at respectively corresponding first and second locations,

wherein the first location is defined at an outer surface of the first optical waveguide away from an output facet of the
first optical waveguide at a proximal end thereof, the second location defined at an output facet of the second optical waveguide
at a proximal end thereof,
and
a detector operably connected with the proximal end to acquire radiation energy and to produce output data representing said
target, said output data including a first data portion representing the first radiation and a second data portion representing
the second radiation.

US Pat. No. 9,326,682

SYSTEMS, PROCESSES AND SOFTWARE ARRANGEMENTS FOR EVALUATING INFORMATION ASSOCIATED WITH AN ANATOMICAL STRUCTURE BY AN OPTICAL COHERENCE RANGING TECHNIQUE

The General Hospital Corp...

1. A process for evaluating at least one image associated with at least one portion of an anatomical structure, comprising:
receiving first information associated with the at least one portion of the anatomical structure;
receiving second information associated with the at least one portion of the anatomical structure;
with a computer processing device, generating third information by determining a relationship between the first information
and the second information; and

with the computer processing device, evaluating the at least one image using a predetermined pathological scoring criteria
and the third information, wherein the predetermined pathological scoring criteria includes at least one of (i) a surface
maturation score measured by patterns of reflectance of nuclear density or (ii) a glandular irregularity score.

US Pat. No. 9,278,353

SORTING PARTICLES USING HIGH GRADIENT MAGNETIC FIELDS

The General Hospital Corp...

1. A microfluidic device comprising:
one or more magnets, wherein each magnet is operable to emit a magnetic field;
a magnetizable layer arranged adjacent to the one or more magnets, wherein the magnetizable layer is configured to induce
a gradient in the magnetic field of at least one of the magnets, wherein the gradient is at least 103 T/m at a position that is at least 20 ?m away from a surface of the magnetizable layer, and wherein the magnetizable layer
comprises

a first high magnetic permeability material, and
a low magnetic permeability material arranged adjacent to or at least partially bordering the high magnetic permeability material;
and

a microfluidic channel arranged on a surface of the magnetizable layer, wherein a central longitudinal axis of the microfluidic
channel is arranged at an angle to or laterally offset from an interface between the first high magnetic permeability material
and the low magnetic permeability material.

US Pat. No. 9,186,066

APPARATUS FOR APPLYING A PLURALITY OF ELECTRO-MAGNETIC RADIATIONS TO A SAMPLE

The General Hospital Corp...

1. An apparatus for applying a plurality of electro-magnetic radiations to a sample, comprising:
a first arrangement which is configured to provide the radiations, at least two of which are separated into a first radiation
to be provided to the sample, and an additional radiation to be provided to a reference arm;

a catheter second arrangement having a specific portion with a plurality of channels, wherein one of the channels facilitates
the first radiation to be forwarded to the sample that is within an anatomical structure, and another one of the channels
facilitates a second radiation of the radiations to be forwarded to the sample, the first radiation having a first wavelength
band, and the second radiation having a second wavelength band, wherein the first wavelength band is different from the second
wavelength band,

wherein the channels further include a first fiber transmitting the first and second radiations, and wherein the first and
second radiations transmitted via the first fiber are separated within a catheter body of the catheter second arrangement,
and provided into the one of the channels having a second fiber and the other one of the channels having a third fiber, wherein
the catheter body in which the separated first and second radiations are transmitted is configured to be inserted into the
anatomical structure;

a processor third arrangement configured to (i) receive first information associated with the first radiation reflected from
the sample, and (ii) determine an effect of the second radiation on the sample based on the first information; and

a rotary coupler arrangement which receives the radiations via at least one fourth fiber and provides the first radiation
to the first fiber, wherein, when activated, the rotary coupler arrangement causes the specific portion to be continuously
rotated within the anatomical structure.

US Pat. No. 9,176,319

METHODS, ARRANGEMENTS AND APPARATUS FOR UTILIZING A WAVELENGTH-SWEPT LASER USING ANGULAR SCANNING AND DISPERSION PROCEDURES

The General Hospital Corp...

1. An apparatus for filtering an electromagnetic radiation, comprising:
at least one first arrangement configured to receive at least one first electro-magnetic radiation and forward at least one
second electro-magnetic radiation at different angles with respect to a direction of incidence of the at least one first electro-magnetic
radiation; and

at least one wavelength dispersion second arrangement configured to receive the at least one second electro-magnetic radiation,
intentionally forward at least one third electro-magnetic radiation to the at least one first arrangement and further receive
at least one fourth electro-magnetic radiation, wherein the at least one third electro-magnetic radiation is a return radiation
from the at least one wavelength dispersion second arrangement based on the at least one second electro-magnetic radiation,
and wherein the at least one fourth electro-magnetic radiation is a direct reflection of the at least one third electro-magnetic
radiation from the at least one first arrangement.

US Pat. No. 9,925,161

COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF

The General Hospital Corp...

1. A method of inducing weight loss in a pre-obese, obese, or morbidly obese subject, comprising orally administering to the subject an effective amount of between 0.005 mg and 1.0 mg per kg body weight of the subject per day of a celastrol compound having the structure:
to reduce food intake in the subject.

US Pat. No. 9,522,031

METHOD AND APPARATUS FOR DERMATOLOGICAL HYPOPIGMENTATION

The General Hospital Corp...

1. A method for gradually lightening an area of a skin tissue of a patient, the method comprising:
identifying the area of the skin tissue to be treated with hypopigmentation; and
treating the area of the skin tissue of the patient by locally freezing the area of the skin tissue with a cooling arrangement
having a temperature between ?4° C. to ?30° C. to provide controlled heat extraction from the skin tissue; and freezing a
dermal-epidermal junction of the area of the skin tissue

wherein the local freezing of the area of the skin tissue with the cooling arrangement having the temperature between ?4°
C. to ?30° C. generates a hypopigmentation effect in the area of the skin tissue.

US Pat. No. 9,445,905

FEMORAL HEADS, MOBILE INSERTS, ACETABULAR COMPONENTS, AND MODULAR JUNCTIONS FOR ORTHOPEDIC IMPLANTS AND METHODS OF USING FEMORAL HEADS, MOBILE INSERTS, ACETABULAR COMPONENTS, AND MODULAR JUNCTIONS FOR ORTHOPEDIC IMPLANTS

The General Hospital Corp...

1. An orthopedic implant comprising:
a femoral head implant that includes an outer surface having a peripheral portion that is contoured so as to achieve an inward
shift of the outer surface relative to an overall spherical geometry of the femoral head implant;

wherein the femoral head implant has a femoral head rim comprising an edge or surface marking an end of a femoral head articular
surface of the femoral head implant,

wherein the femoral head implant has a femoral head axis defined by a reference line passing through a center of the overall
spherical geometry of the femoral head implant to a geometric center of the femoral head rim of the femoral head implant,

wherein the inward shift occurs at an angle greater than about 80° measured from an intersection of the femoral head axis
with the outer surface of the femoral head implant, and

wherein the peripheral portion that is contoured extends to the femoral head rim, and the inward shift of the outer surface
is achieved using only a convex radius or convex radii that immediately follow a non-contoured surface.

US Pat. No. 9,394,384

TOUGH HYDROGELS

The General Hospital Corp...

1. A method of making a tough hydrogel, the method comprising:
(a) heating a polymeric material and a gellant and mixing the heated polymeric material with the heated gellant to form a
gelling solution having a temperature above room temperature and cooling the gelling solution to room temperature thereby
forming an as-gelled hydrogel, the gellant being a non-solvent for the hydrogel;

(b) annealing the as-gelled hydrogel by heating to a temperature that is below the melting point of the as-gelled hydrogel
that is being annealed, wherein the non-solvent gellant remains in the as-gelled hydrogel during annealing and prevents collapse
of porosity in the as-gelled hydrogel; and

(c) cooling the heated as-gelled hydrogel to room temperature, thereby forming a tough hydrogel,
wherein the gellant comprises polyethylene glycol.

US Pat. No. 9,128,091

CAPTURING PARTICLES

The General Hospital Corp...

1. A method for capturing cells suspended in a blood sample, the method comprising:
flowing the blood sample including the cells to be captured through a microchannel comprising an inner wall surface, wherein
at least one V-shaped groove is defined in the inner wall surface of the microchannel, wherein the at least one V-shaped groove
comprises an apex and two arms connected to the apex and is oriented such that the apex points in the direction of flow through
the microchannel, and wherein an adherent is disposed on the inner wall surface in which the at least one V-shaped groove
is defined;

contacting at least some of the cells against the adherent; and
capturing at least some of the cells contacting the adherent.
US Pat. No. 10,030,057

BIODEGRADABLE MATRIX COMPRISING STEM CELLS THAT EXPRESS SOLUBLE TRAIL

THE GENERAL HOSPITAL CORP...

9. A biodegradable matrix or scaffold that permits stem cell migration from said matrix or scaffold, the matrix or scaffold comprising a stem cell comprising a heterologous nucleic acid sequence encoding a soluble TRAIL polypeptide comprising an extracellular domain of human TRAIL of SEQ ID NO: 1.

US Pat. No. 10,022,357

AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYNDROME AND ALZHEIMER'S DISEASE

THE GENERAL HOSPITAL CORP...

1. A method of treating a neurodegenerative disorder in a subject, the method comprising administering to the subject in need thereof an effective amount of a compound selected from compounds of Formulas I-XII, or a pharmaceutically acceptable salt thereof:

US Pat. No. 9,557,154

SYSTEMS, DEVICES, METHODS, APPARATUS AND COMPUTER-ACCESSIBLE MEDIA FOR PROVIDING OPTICAL IMAGING OF STRUCTURES AND COMPOSITIONS

The General Hospital Corp...

1. An arrangement for providing at least one electro-magnetic radiation to an anatomical structure, comprising:
at least one optical core and at least one cladding at least partially surrounding the at least one core with a region therebetween,
wherein the region has an index that is different from indices of the at least one optical core and the at least one cladding;

at least one optical apparatus which includes a lens configuration that is configured to direct the at least one radiation
via at least one of the at least one optical core or the at least one cladding to the anatomical structure; and

at least one optical system which is configured to receive, through the lens configuration, at least two radiations from the
anatomical structure via at least one of the at least one optical core or the at least one cladding.

US Pat. No. 9,439,673

METHOD AND APPARATUS FOR SKIN RESURFACING

The General Hospital Corp...

1. An apparatus for producing a cosmetic effect in a region of skin tissue, comprising:
a plurality of hollow needles configured to remove portions of the skin tissue when the plurality of hollow needles are repeatedly
inserted into and withdrawn from the skin tissue, so as to produce the cosmetic effect,

wherein:
(i) the apparatus is configured to remove an areal fraction of the skin tissue that is about 0.1; and
(ii) the apparatus further comprises:
a) a filter arrangement and container for capturing the portions of the skin tissue to be discarded; and
b) a reciprocating arrangement configured to translate the plurality of hollow needles over the skin tissue in one direction
or two orthogonal directions.

US Pat. No. 9,358,149

SYSTEMS FOR AFFECTING SUBCUTANEOUS LIPID-RICH CELLS, SYSTEMS FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS, AND SYSTEMS FOR REDUCING SUBCUTANEOUS LIPID-RICH CELLS

The General Hospital Corp...

2. A system for affecting subcutaneous lipid-rich cells of a target region of a subject, comprising:
a treatment unit including a cooling element and a mechanical motion device; and
a control unit programmed to control operation of the cooling element to lower a temperature of the target region to disrupt
the subcutaneous lipid-rich cells while non-lipid-rich cells of the subject are generally not injured;

wherein the mechanical motion device is operable to provide mechanical motion to the target region; and
wherein the control unit is further programmed to command the mechanical motion device to provide mechanical motion to the
target region after lowering the temperature of the subcutaneous lipid-rich cells.

US Pat. No. 9,289,128

IN VIVO FLOW CYTOMETRY BASED ON CELLULAR AUTOFLUORESCENCE

The General Hospital Corp...

1. A method of performing in vivo flow cytometry, comprising illuminating at least a portion of blood circulating through
a blood vessel in a live subject with radiation so as to excite at least one or more intrinsic cellular fluorophores of a
plurality of circulating cells, and flow cytometrically detecting fluorescence radiation signal emitted by said one or more
intrinsic cellular fluorophores in one or more of the circulating cells in response to said excitation.
US Pat. No. 9,242,015

DEVELOPMENT AND SCREENING OF CONTRAST AGENTS FOR IN VIVO IMAGING OF PARKINSON'S DISEASE

The General Hospital Corp...

1. A method for in vivo imaging of an ?-synuclein aggregate, the method comprising:
a) administering, to a subject in need thereof, a detectable amount of a compound selected from the group consisting of 3,3?-diethylthiadicarbocyanine
iodide (3-3?-DTDCI); 4-[4-[4-(dimethylamino)phenyl]-1,3-butadienyl]-1-ethyl-pyridinium perchlorate (LDS 722); LDS 759; 4-[4-[4-(dimethylamino)phenyl]-1,3-butadienyl]-1-ethyl
quinolinium (LDS 798); 9-diethylamino-5-benzo[?]phenoxazinone (Nile Red); THK-265; 2-[4-[4-(dimethylamino)phenyl]-1,3-butadienyl]-1,3,3-trimethyl-3H-indolium
perchlorate (LDS 730); 5-amino-9-(diethylamino)-benzo[a]phenoxazin-7-ium perchlorate (Nile Blue 690 ClO4); 2-[7-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1,3,5-heptatrienyl]-1,3,3-trimethyl-3H-indolium perchlorate (HITC
ClO4); 2,2?-([1,1?-biphenyl]-4.4?-diyldi-2,1-ethenediyl)bis-benzenesulfonic acid disodium salt (Stilbene 420); analogs, isomers
and pharmaceutically acceptable salts thereof; and any combinations thereof; and

b) detecting the contrast agent bound to the ?-synuclein aggregate to image the ?-synuclein aggregate.

US Pat. No. 9,187,421

ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS

THE GENERAL HOSPITAL CORP...

1. A method for providing anesthesia to a subject comprising administering to said subject a compound, or pharmaceutically
acceptable salt thereof, of formula (I):

wherein:
R1 is L1C(O)OL2C(O)OT;

R2 is C1-C10 alkyl;

n is an integer from 0-5;
each R3 is independently halogen or R2;

R4 and R5 are independently H, halogen, CN or CF3;

L1 is a bond or C1-C10 alkylene;

L2 is a bond or C1-C10 alkylene;

T is H, a C1-C10 alkyl, C1-C10 alkyl substituted with an electron withdrawing group, C2-C10 alkenyl, C2-C10 alkenyl substituted with an electron withdrawing group, C2-C10 alkynyl, C2-C10 alkynyl substituted with an electron withdrawing group, nitrophenol, or cyclopropyl, wherein the backbone of the alkyl may
contain one or more heteroatom.

US Pat. No. 9,045,749

METHODS TARGETING MIR-128 FOR REGULATING CHOLESTEROL/LIPID METABOLISM

The General Hospital Corp...

1. A method of reducing obesity, treating or reducing predisposition to insulin resistance, and/or treating or reducing predisposition
to type II diabetes, in a subject, the method comprising administering to the subject an inhibitory nucleic acid sequence
that is complementary to all or part of any of SEQ ID NOs:1-6 in an amount sufficient to decrease obesity, treat or reduce
predisposition to insulin resistance, and/or to treat or reduce predisposition to type II diabetes, thereby decreasing obesity,
treating or reducing predisposition to insulin resistance, and/or treating or reducing predisposition to type II diabetes,
in the subject.
US Pat. No. 9,487,828

METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE CONTIGUOUS TO A KNOWN TARGET NUCLEOTIDE SEQUENCE

The General Hospital Corp...

1. A method for determining the nucleotide sequence contiguous to a known target nucleotide sequence of 10 or more nucleotides,
the method comprising:
(i) ligating a universal oligonucleotide tail-adaptor to a nucleic acid comprising the known target nucleotide sequence to
produce a ligation product;

(ii) amplifying the ligation product by polymerase chain reaction using a first adaptor primer that specifically anneals to
the universal oligonucleotide tail-adaptor, and a first target-specific primer that specifically anneals to the known target
nucleotide sequence;

(iii) amplifying an amplification product of (ii) by polymerase chain reaction using a second adaptor primer and a second
target-specific primer, wherein the second adaptor primer and the second target-specific primer are nested relative to the
first adaptor primer and the first target-specific primer, respectively; and

(iv) sequencing an amplification product of (iii) using a first sequencing primer and a second sequencing primer, wherein
the first sequencing primer and the second sequencing primer are complementary to opposite strands of the amplification product
of (iii).

US Pat. No. 9,457,057

METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS

The General Hospital Corp...

1. A method for treating wound contraction in a burned tissue in a subject in need thereof, comprising administering to the
subject an effective amount of a peptide having the formula D-Arg-2?,6?-dimethyltyrosine-Lys-Phe-NH2.
US Pat. No. 9,388,412

INHIBITORS OF MICRORNAS THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF

The General Hospital Corp...

1. A method for treating a subject with hypertension, the method comprising administering to the subject an effective amount
of nucleic acid inhibitor of miRNA-425 activity, wherein the subject is determined to be homozygous (AA) or heterozygous (AG)
for A allele for the single nucleotide polymorphism (SNP) rs5068 (A/G).

US Pat. No. 9,347,595

SYSTEMS AND METHODS FOR PARTICLE FOCUSING IN MICROCHANNELS

The General Hospital Corp...

1. A system for focusing particles having a diameter (a) suspended within a moving fluid having a kinematic viscosity (v)
into one or more localized stream lines, the system comprising:
a substrate;
at least one focusing channel provided on the substrate, wherein the at least one focusing channel comprises an inlet and
an outlet and has a hydraulic diameter (Dh) configured such that a ratio of the particle diameter a to the hydraulic diameter Dh is greater than or equal to about 0.07 and less than or equal to about 0.5;

and
a pumping element controlled to flow the moving fluid through the at least one focusing channel in a laminar flow at a maximum
channel velocity (Um) sufficient to maintain a channel Reynolds number (Rc) of the fluid flow greater than or equal to about 1 and less than or equal to about 250, wherein


such that inertial forces act on the particles and focus the particles having diameter a into one or more localized stream
lines within the moving fluid in the at least one focusing channel.

US Pat. No. 9,333,064

VAGINAL VAULT SUSPENSION DEVICE AND METHOD

The General Hospital Corp...

1. A device for treating pelvic organ prolapse in a patient, the device comprising:
a first flexible attachment part including a base section and a flap extending away from the base section, the base section
being suitable for affixing to a sacrum or tissue adjacent the sacrum of the patient; and

a second separate flexible attachment part including an opening and a slot adjacent the opening, the second attachment part
being suitable for affixing to the pelvic organ of the patient,

wherein the flap of the first attachment part is looped though the opening and the slot in the second attachment part and
the flap is attached to the first attachment part thereby suspending the pelvic organ from the sacrum or the tissue adjacent
the sacrum of the patient, and

wherein the opening of the second attachment part is configured to allow visualization of an attachment site of the first
attachment part when the first attachment part is in a tensioned position as attached to the attachment site when performing
a procedure through an incision in a vagina.

US Pat. No. 9,181,197

ETOMIDATE ANALOGUES WITH IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES

THE GENERAL HOSPITAL CORP...

1. A compound according to formula (I)
wherein,
R1 is L1C(O)OT;

R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1;

n is an integer from 0-5;
each R3 is independently halogen or R2;

L1 is unsubstituted C1-C10 alkylene, substituted or unsubstituted C2-C10 alkenylene, or substituted or unsubstituted C2-C10 alkynylene, wherein the backbone of alkylene may contain one or more heteroatoms;

T is H, a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenylene, C2-C10 alkynylene, nitrophenol, or cyclopropyl, wherein the backbone of alkyl may contain one or more heteroatoms; and

pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof,
provided that when R1 is L1C(O)OT, R2 is CH3, R3 fluorine, n is 1, and T is CH2CH3.

US Pat. No. 9,173,572

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR TRACKING VESSEL MOTION DURING THREE-DIMENSIONAL CORONARY ARTERY MICROSCOPY

The General Hospital Corp...

1. An apparatus for determining at least one characteristic of a structure, comprising:
at least one transceiver first arrangement which is structured to provide at least one first transmitted radiation along a
first axis and at least one second transmitted radiation along a second axis, wherein the first and second transmitted radiations
impact the structure and generate respective first and second returned radiation, and wherein the first and second axes are
provided at a predetermined angle with respect with one another which is greater than 0;

at least one computer second arrangement which is configured to receive data associated with the first and second returned
radiation, and determine at least one relative velocity between the structure and the at least one first arrangement; and

at least one imaging third arrangement which is configured to generate at least one image of at least one portion of the structure
as a function of the at least one relative velocity.

US Pat. No. 9,095,357

METHOD AND APPARATUS FOR DERMATOLOGICAL TREATMENT AND TISSUE RESHAPING

The General Hospital Corp...

1. A skin treatment method comprising:
inserting a plurality of needles into a dermal layer of skin, the plurality of needles being attached to a base, the plurality
of needles being further configured to receive radio frequency (RF) energy from a RF energy source; and

regulating delivery of the RF energy from the RF energy source to the plurality of needles to induce a pattern of fractional
damage by the RF energy in the dermal layer when the needles are inserted therein, wherein the regulation of the delivery
of the RF energy is configured to stimulate formation of new collagen in the skin.

US Pat. No. 9,944,912

ENGINEERED CRISPR-CAS9 NUCLEASES WITH ALTERED PAM SPECIFICITY

The General Hospital Corp...

1. An isolated nucleic acid encoding a variant Streptococcus pyogenes (SpCas9) protein comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1, with an amino acid mutation at D1135 and optionally at one or more of the following positions: G1104, 51109, L1111, 51136, G1218, N1317, R1335, or T1337.
US Pat. No. 9,730,963

CELL TRANSPLANTATION

The General Hospital Corp...

1. A method for transplanting adipocytes, the method comprising:
administering a composition of adipocytes and a non-ionic triblock copolymer to a subject, wherein the copolymer comprises
a central hydrophobic core flanked by two hydrophilic tails protects the adipocytes from injury and adipocyte death, and is
present in a concentration of about 10 mg to about 20 mg of copolymer per mL of adipocytes, wherein the non-ionic triblock
copolymer is poloxamer P184.

US Pat. No. 9,528,154

METHODS AND COMPOSITIONS FOR IDENTIFYING UNDIFFERENTIATED STEM CELLS AND ASSESSING CELL HEALTH

The General Hospital Corp...

1. A method for determining the differentiation state of a pluripotent stem cell, wherein said stem cell is one of a population
of stem cells, said method comprising:
(a) contacting said stem cell with a heterogeneous Cot-1 nucleic acid probe under conditions for hybridization of the heterogeneous
Cot-1 nucleic acid probe to a ribonucleic acid molecule in the nucleus of said stem cell; and

(b) detecting the hybridization of said heterogeneous Cot-1 nucleic acid probe to the ribonucleic acid molecule in the stem
cell, wherein the hybridization of the heterogeneous Cot-1 nucleic acid probe to the ribonucleic acid molecule in the stem
cell is detected as a teloRNA mark in situ using fluorescent in situ hybridization (FISH),

wherein the presence of two teloRNA marks, one on each sex chromosome, identifies said stem cell as a stem cell that is undifferentiated
and the presence of only one teloRNA mark on an inactive X chromosome in a female stem cell or a Y chromosome in a male stem
cell identifies said stem cell as a stem cell that is differentiated.

US Pat. No. 9,516,997

SPECTRALLY-ENCODED ENDOSCOPY TECHNIQUES, APPARATUS AND METHODS

The General Hospital Corp...

1. An apparatus for obtaining information for a structure, comprising:
at least one first optical fiber arrangement configured to transceive at least one first electro-magnetic radiation, and including
at least one fiber;

at least one dispersive second arrangement configured to receive a particular radiation which is at least one of the at least
one first electro-magnetic radiation, and forward a spectrally-dispersed radiation thereof to at least one section of the
structure; and

at least one focusing third arrangement in an optical communication with the at least one first optical fiber arrangement,
wherein the at least one third arrangement is configured to focus and provide there through the spectrally-dispersed radiation
to generate a focused electro-magnetic radiation, and

wherein at least one end of the at least one fiber is connected to at least one of the at least one focusing third arrangement
and or the at least one dispersive second arrangement.

US Pat. No. 9,475,868

ANTIBODIES THAT SPECIFICALLY BIND TO DRG11-RESPONSIVE (DRAGON) PROTEINS

THE GENERAL HOSPITAL CORP...

1. An antibody that specifically binds to an amino acid sequence contained within the amino acid sequence of SEQ ID NO: 5.

US Pat. No. 9,447,027

TREATING LONG QT SYNDROME

The General Hospital Corp...

1. A method for treating long QT syndrome in a patient in need thereof, the method comprising administering to the patient
a therapeutically effective amount of one or more compounds of Formula (1):

or a pharmaceutically acceptable salt form thereof,
wherein:
R1 is selected from the group consisting of: hydrogen, halo, (C1-C6)alkyl, (C1-C6)haloalkyl, —O(C1-C6)alkyl, and —C(O)R3;

R2 is selected from the group consisting of: hydrogen, (C1-C6)alkyl, and —O(C1-C6)alkyl; and

R3 is selected from the group consisting of: hydrogen and (C1-C6)alkyl; or a pharmaceutically acceptable salt form thereof.

US Pat. No. 9,410,144

BLOOD CELL SORTING METHODS AND SYSTEMS

The General Hospital Corp...

1. A method of isolating white blood cells from a whole blood sample, the method comprising:
(a) obtaining a sample comprising whole blood;
(b) decreasing viscosity of the sample;
(c) contacting the sample with a magnetic particle that binds specifically to white blood cells or a subset of white blood
cells to provide a white blood cell/magnetic particle complex; and

(d) isolating the white blood cell/magnetic particle complex from the whole blood sample by subjecting the white blood cell/magnetic
particle complex to a magnetic field at a strength and for a time sufficient to achieve a final cell yield of greater than
75% and a white blood cell viability of greater than 90%.

US Pat. No. 9,351,792

METHOD AND APPARATUS FOR DERMATOLOGICAL TREATMENT AND FRACTIONAL SKIN RESURFACING

The General Hospital Corp...

1. A method for treating dermatological conditions, comprising:
controlling an electromagnetic radiation source to generate an electromagnetic radiation;
causing the electromagnetic radiation to be applied to a target area of skin; and
preventing at least one portion of the target area of the skin from being exposed to the electromagnetic radiation;
wherein the radiation is configured to at least one of thermally damage or ablate epidermal tissue and dermal tissue of the
target area of the skin extending from a surface of the skin through an entire depth of the epidermal tissue and to at least
a particular depth within the dermal tissue of the skin, and

wherein a width of the at least one portion of the target area is at least 50 ?m and at most 300 ?m.
US Pat. No. 9,186,336

METHODS OF TREATING VASCULAR LESIONS

The General Hospital Corp...

1. A method of treating laryngeal recurrent respiratory papillomatosis (RRP) and maintaining or improving mucosal pliability
in the larynx in a human subject, the method comprising locally administering to a phonatory mucosal surface in the larynx
of the subject in need thereof an anti-VEGF antibody that binds to human VEGF-A in an amount effective to inhibit RRP and
to maintain or improve mucosal pliability in the larynx.

US Pat. No. 9,138,294

METHOD AND APPARATUS FOR SELECTIVE PHOTOTHERMOLYSIS OF VEINS

The General Hospital Corp...

1. A method for treating a region of interest (ROI) of a patient's body, the method comprising:
identifying an ROI of skin of the patient's body, said identified ROI including at least one venous malformation;
treating the identified ROI with light having an operational wavelength at which blood in a typical vein in human skin has
an absorption coefficient that at least 3.7 times higher than an absorption coeffiecient of a typical artery in human skin
such as to photocoagulate a vein by selective photothermolysis of the at least one venous malformation while avoiding damage
to an artery within the skin of the ROI;

said blood containing about 30 percent deoxyhemoglobin and about 70 percent oxyhemoglobin.

US Pat. No. 9,486,447

COMPOSITIONS AND METHODS FOR CONTROLLING NEURONAL EXCITATION

The General Hospital Corp...

1. A method of modulating the activity of a neuron, the method comprising;
a) contacting the neuron with a compound of formula Ia or Ib:

wherein R11 is hydrogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted
or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted
or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —C(?O)RB; —CO2RB; or —C(RB)3; wherein each occurrence of RB is independently hydrogen; halogen; a protecting group; aliphatic; heteroaliphatic; acyl; aryl moiety; heteroaryl; hydroxyl;
aloxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy; heteroarylthioxy; or alkylhalo;

R12, R13, and R14, are independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched
or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched
heteroaryl; —C(?O)RB; —CO2RB; -; —CN; —SCN; —SRB; —SORB; —SO2RB; —NO2; —N(RB)2; —NHC(O)RB; or —C(RB)3; wherein each occurrence of RB is independently hydrogen; halogen; a protecting group; aliphatic; heteroaliphatic; acyl; aryl moiety; heteroaryl; hydroxyl;
aloxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy; heteroarylthioxy; or alkylhalo;

R15 is hydrogen;

Y1 is O;

Y2 is S;

X1 is NH;

X2 is NH or S; and

b) exposing the neuron to electromagnetic radiation comprising a wavelength of from about 300 nm to about 700 nm.

US Pat. No. 9,441,948

APPARATUS, METHODS AND STORAGE MEDIUM FOR PERFORMING POLARIZATION-BASED QUADRATURE DEMODULATION IN OPTICAL COHERENCE TOMOGRAPHY

The General Hospital Corp...

1. An apparatus comprising:
a first structural arrangement which includes a radiation generator source providing a particular radiation, a coupler and
a beam splitter, the beam splitter splitting the particular radiation into a first optical electro-magnetic radiation which
is to a sample and a second optical electro-magnetic radiation to a reference, wherein the source causes the particular radiation
to have a spectrum which changes over time;

an optical second structural arrangement which includes a polarization beam combiner that combines a first polarization component
of a third radiation based on the first radiation and a second polarization component of a fourth radiation based on the second
radiation with one another, wherein the polarization beam combiner is part of a configuration which ensures that the first
and second polarization components are at least approximately orthogonal to one another;

a third arrangement which includes a first optical detector that detects a first optical signal derived from a first interference
between a first set of the first and second polarization components to generate a first digital signal, wherein the third
arrangement includes a second optical detector that detects a second optical signal derived from a second interference between
a second set of the first and second polarization components to generate a second digital signal; and

a fourth arrangement which includes a computer that modifies at least one of the first digital signal or the second digital
signal based on particular data such that the first and second digital signals are in a quadrature relationship with one another.

US Pat. No. 9,417,244

CADHERINS AS CANCER BIOMARKERS

The General Hospital Corp...

1. A method of diagnosing cancer in a subject, the method comprising:
providing a sample comprising blood from the subject; and
separating cells that express a cancer cell surface marker from the sample by contacting the sample with a device for separation
of the cells in a sample, the device comprising an inlet, and outlet, and one or more surfaces coated with antibodies or antigen-binding
fragments thereof that bind to each of cancer cell surface markers cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11,
CDH17, CDH19, protocadherin 9 (PCDH9) and PCDH beta 13 (PCDHb13), under conditions sufficient to allow binding of the antibodies
or antigen-binding fragments thereof to cells expressing the surface marker;

detecting the presence of separated cells that express a cancer cell surface marker on a cell in the sample; and
identifying the subject as having cancer based on the presence of a cell that expresses a cancer cell surface marker in the
sample.

US Pat. No. 9,200,017

MULTIMODAL IMAGING OF FIBRIN

The General Hospital Corp...

1. An imaging agent selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
US Pat. No. 10,130,680

METHODS FOR TREATING CANCER WITH EGFR NANOBODIES LINKED TO DR5 BINDING MOIETIES

THE GENERAL HOSPITAL CORP...

1. A method comprising administering, to a subject in need of treatment for cancer, a therapeutically effective amount of a composition selected from the group consisting of:a multifunctional receptor targeted cancer therapeutic comprising a first portion comprising a nanobody reagent that specifically binds EGFR and EGFRvIII to inhibit EGFR signaling and a second portion comprising a therapeutic molecule that specifically binds DR5 to activate apoptosis, wherein the cancer therapeutic binds specifically to targets on the same cancer cell; and
a stem cell comprising an expression vector comprising a nucleic acid molecule encoding a multifunctional receptor targeted cancer therapeutic comprising a first portion comprising a nanobody reagent that specifically binds EGFR and EGFRvIII to inhibit EGFR signaling and a second portion comprising a therapeutic molecule that specifically binds DR5 to activate apoptosis, wherein the cancer therapeutic binds specifically to targets on the same cancer cell.
US Pat. No. 9,655,977

BIOTIN COMPLEXES FOR TREATMENT AND DIAGNOSIS OF ALZHEIMER'S DISEASE

The General Hospital Corp...

1. A composition comprising a biotin moiety and a siRNA moiety, wherein the siRNA moiety comprises a nucleotide of SEQ ID
NO: 1 or a nucleic acid that has at least 95% sequence homology with SEQ ID NO:1.
US Pat. No. 9,314,499

ANNEXIN A2 AND TISSUE PLASMINOGEN ACTIVATOR FOR TREATING VASCULAR DISEASE

The General Hospital Corp...

12. A method comprising:
a) providing:
i) a human patient exhibiting at least one fibrin clot associated with a recently incurred stroke,
ii) a medium comprising Annexin A2 and tissue plasminogen activator (tPA), wherein said Annexin A2 and said tPA have a dose
ratio of 2:1; and,

b) administering said medium to said human patient under conditions such that lysis of said at least one fibrin clot is increased.

US Pat. No. 9,220,411

IN-VIVO OPTICAL IMAGING METHOD INCLUDING ANALYSIS OF DYNAMIC IMAGES

THE GENERAL HOSPITAL CORP...

1. An in-vivo optical molecular imaging method for producing an image of an animal, comprising:
acquiring, from an animal positioned on an imaging platform, a time series of image data sets of a targeted optical contrast
substance within the animal, the time series obtained by taking a plurality of images at distinct times following introduction
of the contrast substance into the animal, using an optical detector, wherein each image data set is obtained at a selected
time and has the same plurality of pixels, with each pixel having an associated value for each time in the time series, the
imaging platform having a surface for supporting the subject in a desired arrangement in a field of view of an optical detector
operable to acquire an image of a subject within the field of view,

and wherein at least one mirror is arranged at an angle with respect to the imaging platform surface such that multiple views
of the subject are within the field of view of the optical detector, and

wherein a processor is configured to process image data received from the optical detector;
determining a plurality of distinctive time courses based on the image data sets,
analyzing the image data sets to separate, for each pixel of a plurality of pixels, the associated values into a plurality
of components, each of which is associated with one of the time courses, and

generating an image of the animal wherein the value at each pixel of the generated image corresponds to the value of the component
associated with a single time course,

wherein time courses are (Torg1(t), Torg2(t), . . .) and the time courses are used in a linear non-negative least-squares fit to image time series data M(r,t) to
resolve spatial distribution of pixels r with t time course (Iorg1(r), Iorg2(r), by solving:


and wherein the steps of acquiring, determining, analyzing and generating are performed on a machine-readable medium that
includes instructions executable by the processor.

US Pat. No. 9,175,043

AGENTS PROVIDING CONTROLS AND STANDARDS FOR IMMUNO-PRECIPITATION ASSAYS

The General Hospital Corp...

1. A polypeptide-oligonucleotide conjugate of the formula:
A-L-N,wherein A is a polypeptide comprising 5 amino acids, L is a chemical linker, and N is an oligonucleotide comprising 10 nucleotides,
wherein a sequence of nucleotides of N uniquely identifies an amino acid sequence and/or amino acid modification of A, and
wherein A comprises an amino acid sequence derived from a histone protein selected from the group consisting of histone H1,
H2A, H2AX, H2B, H3 and H4.

US Pat. No. 10,018,700

CORRECTING FOR MAIN MAGNETIC FIELD INHOMOGENEITY IN MRI SCANNERS

University of Cape Town, ...

1. A method of correcting for main magnetic field (B0) inhomogeneity in a Magnetic Resonance Imaging (MRI) scanner during a scanning sequence which includes the acquisition of successive volumes by means of Magnetic Resonance (MR) pulse sequences, comprising:after an acquisition of a volume in the scanning sequence:
applying, by the MRI scanner, a first three-dimensional volumetric navigator and obtaining a first navigator image,
applying, by the MRI scanner, a second three-dimensional volumetric navigator after the first navigator and obtaining a second navigator image, wherein the first and second navigators have different echo times;
after the first and second navigator images have been obtained and before the acquisition of the next volume in the scanning sequence:
determining a magnetic field map by complex division of the first and second navigator images;
using the magnetic field map to determine parameters required to adjust the homogeneity of the main magnetic field (B0), the determined parameters including a zero order shim which is estimated from the magnetic field map based on a least-squares fit; and
adjusting the MRI scanner based on the determined parameters by adjusting a system central frequency of the MRI scanner, the system central frequency being adjusted by adjusting a phase and frequency for a Numerically Controlled Oscillator (NCO) of the MRI scanner for all radiofrequency (RF) excitation pulses of the MRI scanner and for Analog to Digital Converter (ADC) pulses of the MRI scanner for both the scanning sequence and for the first and second navigators.
US Pat. No. 10,288,610

VITRO ASSAYS FOR DETECTING SALMONELLA ENTERICA SEROTYPE TYPHI

THE GENERAL HOSPITAL CORP...

1. A microfluidic device comprising:at least one S. Typhi specific antigen selected from the group consisting of STY1364 (SEQ ID NO: 1); STY2657 (SEQ ID NO: 2); HCM2.0069c (SEQ ID NO: 3); HCM2.0043 (SEQ ID NO: 4); HCM1.137 (SEQ ID NO: 5); STY2386 (SEQ ID NO: 6); STY1479 (SEQ ID NO: 7); STY2454 (SEQ ID NO: 8); STY2248 (SEQ ID NO: 9); STY3709 (SEQ ID NO: 10); STY2155 (SEQ ID NO: 11); HCM1.213c (SEQ ID NO: 12); and STY0712 (SEQ ID NO: 13);
one or more 5-120 consecutive amino acid fragments of said selected antigen; or
any combination thereof.

US Pat. No. 9,968,259

SYSTEMS AND METHODS FOR SENSING, ENUMERATING AND IMAGING RARE CELLS WITH DIFFUSE LIGHT

NORTHEASTERN UNIVERSITY, ...

1. A diffuse fluorescence flow cytometer comprising:a plurality of excitation sources adapted to be positioned circumferentially about a space sized for accommodating a limb of a subject, the limb comprising cells circulating therewithin, the cells being labeled with a fluorophore, wherein all of the excitation sources emit light having the same wavelength;
a plurality of detectors adapted to be positioned circumferentially about the space for (i) collecting a fluorescent emission from the cells generated in response to the light from each excitation source, and (ii) generating signals in response thereto, wherein-each of the detectors comprises an optical fiber having a first end angled toward the space;
a plurality of first bandpass filters, each of the first bandpass filters being (i) interposed between the space and one of the plurality of detectors and (ii) tuned to an emission peak of the fluorophore;
a plurality of second bandpass filters, each of the second bandpass filters being (i) interposed between the space and one of the excitation sources, and (ii) tuned to the same wavelength, the wavelength to which each of the second bandpass filters is tuned being different than a wavelength to which each of the first bandpass filters is tuned;
a multi-channel photomultiplier tube for receiving signals generated by the detectors from a second end of each of the optical fibers;
a preamplifier configured to (i) amplify the output of the photomultiplier tube, (ii) remove noise from the output of the photomultiplier tube, and (iii) remove a DC signal component from the output of the photomultiplier tube, the DC signal component arising from autofluorescence from the limb;
a photon counter for counting signals output by the preamplifier;
a memory; and
a processor responsive to the plurality of excitation sources and the plurality of detectors and configured to, in accordance with executable instructions stored in non-transitory form in the memory, generate, based on the signals generated by the plurality of detectors after the signals are received by the photomultiplier tube, amplified by the preamplifier, and counted by the photon counter, a tomographic reconstruction showing the position of the fluorescent emission within a cross-section of the limb,
wherein the processor is configured to, in accordance with the executable instructions:
operate the plurality of excitation sources to excite the fluorophore, thereby generating a fluorescent emission, wherein the plurality of excitation sources are operated to individually and sequentially illuminate the limb via emission of light theretoward, such that, for each of the excitation sources in turn, only one of the excitation sources illuminates the limb while all other excitation sources do not emit light, and
operate the plurality of detectors to detect the fluorophore within the limb via collection of the fluorescent emission, wherein the plurality of detectors are operated such that all of the detectors collect fluorescent emission during the sequential illumination by each of the excitation sources.